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Introduction
Microcirculation of nutrients and drugs into the brain 
is selectively controlled by a unique biological barrier 
called blood-brain barrier (BBB). Such biological barrier 
is formed by the brain capillary endothelial cells (BCECs) 
whose maturation and functions is largely dependent 
upon intercellular interaction with brain astrocytes and 
pericytes.1-3 Of the BBB cooperating cells, the astrocytes 
are members of the glial family, which are able to interact 
with neurons and other brain cells (e.g., microglia and 
endothelial cells) directly and/or indirectly through the 
exchange of soluble materials. At the BBB, the astrocytic 
foot process covers 99% of the abluminal surface of the 
capillary basement membrane, while the brain capillary 
pericytes share the basement membrane with BCECs 
(Fig. 1). The BCECs form a co-operating complex with 
astrocytes and pericytes (the “Neurovascular Unit”) to: 
(a) maintain brain homeostasis, (b) selectively control the 
delivery of nutrients and blood-borne solutes to the brain 
parenchyma.1 In addition to other modulation roles of 
astrocytes and pericytes on BCECs (e.g., restrictive tight 
junction (TJ) regulation and differentiation), they are 
also involved in modulating the functional expression of 
transport machineries required for the selective inward/
outward transportation of nutrients and drugs.4
It is now well-documented that the capability of a 
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Article Info Abstract
Introduction: Desired clinical outcome of 
pharmacotherapy of brain diseases largely 
depends upon the safe drug delivery into 
the brain parenchyma. However, due to the 
robust blockade function of the blood-brain 
barrier (BBB), drug transport into the brain 
is selectively controlled by the BBB formed 
by brain capillary endothelial cells and 
supported by astrocytes and pericytes. 
Methods: In the current study, we have 
reviewed the most recent literature on the 
subject to provide an insight upon the role 
and impacts of BBB on brain drug delivery and targeting. 
Results: All drugs, either small molecules or macromolecules, designated to treat brain diseases 
must adequately cross the BBB to provide their therapeutic properties on biological targets within 
the central nervous system (CNS). However, most of these pharmaceuticals do not sufficiently 
penetrate into CNS, failing to meet the intended therapeutic outcomes. Most lipophilic drugs 
capable of penetrating BBB are prone to the efflux functionality of BBB. In contrast, all hydrophilic 
drugs are facing severe infiltration blockage imposed by the tight cellular junctions of the BBB. 
Hence, a number of strategies have been devised to improve the efficiency of brain drug delivery 
and targeted therapy of CNS disorders using multimodal nanosystems (NSs). 
Conclusions: In order to improve the therapeutic outcomes of CNS drug transfer and targeted 
delivery, the discriminatory permeability of BBB needs to be taken under control. The carrier-
mediated transport machineries of brain capillary endothelial cells (BCECs) can be exploited for 
the discovery, development and delivery of small molecules into the brain. Further, the receptor-
mediated transport systems can be recruited for the delivery of macromolecular biologics and 
multimodal NSs into the brain. 
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particular substance to cross the BBB and enter the central 
nervous system (CNS) depends on both the biological 
features (e.g., expression of transporters and enzymes) 
and the physicochemical properties of the compound 
(e.g., molecular weight, lipophilicity, pKa, and hydrogen 
bonding capacity). The molecular trafficking through BBB 
can generally be classified into three categories, including: 
(a) passive diffusion that is largely dependent upon the 
lipophilicity of the molecule, (b) transport via one of a 
large number of solute carriers (SLC superfamily) such 
as those for glucose, organic anions, amino acids, and (c) 
vesicular trafficking system (VTS) through endocytosis 
and transcytosis.5 Of these, the functional expression of 
carrier-mediated transporters (CMTs), which mediate 
both influx and/or efflux machineries, can selectively 
control transport of circulating small molecules between 
blood and brain. Small molecule (<500 Da) penetration 
into the brain parenchyma is dominated by passive 
transcellular diffusion with potential to be subject to 
efflux by members of the ABC (ATP-dependent binding 
cassette -ABC) superfamily such as P-glycoprotein (P-gp) 
(ABCB1) or BCRP (ABCG2) or a member(s) of the multi-
drug resistance protein (MRP) family such as MRP1.6,7 
In contrast polar hydrophilic small molecules (e.g., 
amino acids and carbohydrates) exploit the facilitative 
or passive SLC transport systems, while macromolecular 
biomolecules such as insulin, transferrin (Tf) and 
targeted nanoscale drug delivery systems (DDSs) use 
VTS pathways potentially involving a receptor-mediated 
transporter (RMT).8,9 
In addition, it extracellular vesicles (exosomes and 
ectosomes) are engaged in macromolecular trafficking 
and cellular communications and can be used for targeted 
therapy of diseases such as CNS disorders.10-14 
In this current review article, we provide an overview 
on the biological features of BBB relevant to brain drug 
delivery and targeting by highlighting the potential 
therapeutic importance of BBB transport machinery. 
Experimental models for BBB
In order to evaluate the specific functions of BBB, in 
vivo and in vitro as well as in silico approaches have been 
employed by a number of research groups. Although the 
in vivo investigations provides much more reliable and 
robust physiological context measures of BBB functions, 
conducting animal based studies may encounter with 
some pivotal limitations (e.g., ethical issues of animal 
uses, cost and time restrictions, need for genetically 
modified animal models). Therefore, in vitro cell systems 
can serve as a complementray model to reduce and maybe 
refine later in-vivo investigations.15 Cell-based models 
have capacity to provide relatively high trans-endothelial 
electrical resistance (TEER) values (i.e., about 1000 Ω.cm2), 
which offer some discrimination between transcellular 
and paracellular routes of permeation. We have previously 
examined several cell culture systems and found that the 
isolated primary cultures of brain capillary endothelial 
cells from porcine and bovine offer reliable outcomes.1,4,16-19 
Indeed the ability to use primary cell models or at the very 
least early low passage cells appears particularly important 
in BBB investigations. Clearly for human cell work much 
potential may arise through developments with induced 
pluripotent stem cells (iPSC).20 Beyond permeation per se, 
cell models offer the potential for mechanistic transporter 
investigations.18,21 
Brain drug delivery
A large number of studies on brain drug delivery and 
targeting, using in vitro cell-based BBB models15-19 as well 
as animal models, have sought to address how the brain 
Fig. 1. Schematic representation of the blood-brain barrier, astrocytes and pericytes. Image was adapted with permission from our 
previously published work.1 Note: Not drawn to scale.
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capillary endothelium can be safely and efficiently crossed 
by experimental therapeutics and DDS. As shown in Fig. 
2, the blood-borne substances, nutrients and drugs can 
enter into the CNS through one or more pathways each of 
which has been explored as a mean to overcome the BBB 
restrictiveness. The penetration of drugs into the brain 
may occur by following routs: 
(a) paracellular transportation that is a pathway primarily 
for small hydrophilic substances. In this regard, 
there exist some investigations addressing transient 
relaxing of TJ regulation by means of osmotic22 or 
biologically active agents (e.g., bradykinin, cereport 
and histamine),23-25 
(b) transcellular passive diffusion that is a primary 
route for small lipophilic substances, which could 
be optimized by altering drug physicochemical 
properties,
(c) SLC-mediated transport exploiting the diverse 
members of the SLC family of transporters preset 
within the BBB (e.g., various amino acids),8,26
(d) endocytosis through RMT (e.g., monoclonal 
antibodies (mAbs) specific to various receptors at the 
BBB like Tf receptor, targeted nanomedicines),27-29 
and 
(e) adsorptive endocytosis or pinocytosis (e.g., albumin) a 
relatively low capacity route with non-receptor bound 
material shuttled to the lysosomes for degradation.
It should be noted that conjugation of a drug with a targeting 
peptide/protein or with an antibody (Ab)/aptamer (Ap) 
provides nanoconjugates that can specifically shuttle the 
conjugated drugs into the brain through RMTs.30,31 
Besides, targeted nanosystems (NSs) such as polymeric/
lipidic nanoparticles (NPs) decorated with homing entities 
also provide robust tools for crossing BBB that can be used 
to treat life-threatening diseases such as glioma.32-34 
ABC transporters 
The direct energy-dependent ABC active transporters, 
are primarily localized on the luminal membrane of brain 
microvasculatur cells. ABC transporters possess a common 
structure of transmembrane domains (TMDs) and 
cytosolic nucleotide binding domains (NBDs). The ABC 
superfamily encompasses about 48 distinct transporters 
categorized into 7 families (ABC-A,-B,- C,-D,-E,-F, and 
G). Of these, the most investigated transporter in the BBB 
is that coded by the ABCB1 gene, ie. P-glycoprotein (P-
gp or MDR1) (Fig. 3). As a phosphorylated glycoprotein 
(170 kDa), it plays extremely important role in tumor 
cells resulting in their resistance to anticancer drugs by 
effluxing xenobiotics and metabolites out of the cell. P-gp 
is expressed in both epithelial and endothelial cells that are 
involved in formation of biological barriers such as BBB. 
Table 1 represents ABC transporters function and clinical 
impacts. The functional expression of these transport 
machineries play key roles in the maintenance of brain 
homeostasis, in which traverse of blood-borne substances 
should be specifically regulated.
Impacts of solute carriers (SLCs)
The BBB carrier-mediated transporters belonging to the 
SLC superfamily are comprised of two functional groups 
that include the mediation of solute influx or efflux from 
the cell. 
Influx CMTs
The SLC transporters involved in influx at the BBB may be 
divided into different groups, as follows:
(a) Hexose transport system for glucose and mannose 
such as glucose transporters (i.e., Glut-1 and Glut-
3)50,51
(b) Monocarboxylic acid transport (MCT) system such as 
Fig. 2. Different mechanisms of drug trafficking from blood into the brain. Image was adapted with permission from our previously published 
work.1 Note: Not drawn to scale.
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MCT1 and MCT 8 for transportation of lactate, short-
chain fatty acids, biotin, salicylic acid, valproic acid, 
phenylbutyrate and 3,5,3’-triiodo-L-thyronine52-56
(c) Neutral amino acids transporter (NAAT), system L, 
divided into large (LAT1) and small (LAT2) neutral 
amino acid transporter systems for transportation 
of neutral amino acids and some drugs such as 
L-dopa57-59
(d) Anionic amino acids transporters for transportation 
of aspartate and glutamate60-62
(e) Cationic amino acids transporter, system y+, 
for transportation of L-lysine, L-arginine, and 
L-ornithine63,64
(f) Beta amino acid transporter for transportation of 
β-alanine and taurine65-67
(g) Choline transport system for transportation of choline 
and thiamine through organic cation transporter 
(OCT) family68-70
(h) Nucleoside transport system71
(i) Peptide transporters, including oligopeptide 
transporters (e.g., PepT1, PepT2) and polypeptide 
transport system (e.g., Oatp2, OAT-K1, OATP)72,73
(j) Medium-chain fatty acid transporter.74
In the following, some brief discussion is provided on the 
clinical or biological importance of some of these SLCs at 
the BBB.
Hexose transporters 
The functional expression of glucose transporters 
(GLUTs) was initially identified and characterized using 
D-glucose specific competitor cytochalasin B in the 
cerebral microvessels of rat and pig.75 Later on, Pardridge 
and coworkers showed that the GLUT1 isoform is 
selectively expressed at the BBB by means of Western 
blotting, cytochalasin B binding, and in situ hybridization 
in bovine brain cortex. As a result, they concluded that the 
GLUT1 gene is selectively expressed in the brain capillary 
endothelial cells, where 100% of the glucose transporter 
binding sites at the BBB can be attributed to the GLUT1 
isoform.51 Morgello et al. examined human and monkey 
brain sections recruiting immunoelectron microscopy. 
They showed GLUT1 expression in the gray matter and 
white matter endothelial cells, astrocyte foot processes 
surrounding gray matter blood vessels, and astrocytes 
adjacent to synaptic contacts. While the immunoblots 
of adult human frontal cortex were reported to have two 
forms of GLUT1 (45 and 52 kDa), the immunoblots of 
vessel-depleted frontal lobe showed the 45 kDa form solely 
in gray matter fractions. Such findings confirmed linkage 
to GLUT1 in both astrocyte and astrocyte-associated 
neuronal energy metabolism.76 The modeled structure 
of GLUT1 is shown in Fig. 4. From a clinical viewpoint 
GLUT1 is highly upregulated at the BBB of patients with 
seizures,77 and downregulated in Alzheimer’s disease and 
diabetes.78-79 Dysfunctional mutations in GLUT1 may lead 
to some deficiencies in the transportation of glucose in the 
related diseases.80
Monocarboxylic acid transport system
Monocarboxylate transporters (MCTs) consist of different 
isoforms. Of these, the MCT1, 2, 3 and 4 catalyze the 
proton-linked transport of monocarboxylates (e.g., 
L-lactate) across the plasma membrane,82 the expression 
of MCT4 seems to be largely dependent upon the oxygen 
level of the cell as a hypoxia-dependent process.83 Hypoxia 
may affect the expression of MCT1 and 2 and is mediated 
by the hypoxia inducible factor 1α (HIF-1α) that is 
overexpressed in tumor cells.84 These transporters play 
pivotal metabolic roles in most tissues, including the brain 
and other tissues. The MCT8 and MCT10 are respectively 
involved in the transportation of thyroid hormones as well 
as some aromatic AAs through the BBB.56,85,86 Inhibition 
of MCT1 by its specific inhibitors may provide a new 
Fig. 3. Ribbon style representation of the modeled multidrug resistance protein 1 (MDR1). (A) The residues that are correlated ligand 
binding site are magnified. Panel B and C show the two ATP-specific binding sites in MDR1 structure. The UCSF Chimera v1.11 standalone 
software (freely available at: http://www.rbvi.ucsf.edu/chimera) and Visual Molecular Dynamics (VMD) (freely available at: https://www-s.
ks.uiuc.edu/Research/vmd/) were used for visualization of MDR1. 
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treatment horizon in cancer chemotherapy in particular 
for glioblastomas (GBM).87,88 This type of malignancy 
with high cellular heterogeneity and conspicuous necrotic 
regions is largely associated with hypoxia, in which the 
functional expressions of MCT1 and GBM hypoxia marker 
carbonic anhydrase 9 (CAIX) play key roles. It seems that 
dysregulated pH in the tumor microenvironment (TME) 
may pose a significant role in metabolic path of such 
malignancies.89,90 
Amino acid transporters 
Several amino acid transporters function at the BBB to 
maintain brain homeostasis. Of these, the glycoprotein-
associated amino acid transporters (gpaATs) play an 
important role in AAs homeostasis in brain parenchyma. 
These transporters are basically part of the amino acid/
polyamine/choline (APC) superfamily that is considered 
as one of the largest families of transporters. Table 2 lists 
some of the key amino acid transporters. The function of 
neutral amino acid transporter(s) is of note due to their 
involvement in several crucial events in CNS including 
synthesis of the neurotransmitters and peptides/proteins. 
Based upon the binding affinity of a particular transporter 
to AAs, along with its dependency to sodium ion, 
amino acid transporters can be classified into different 
groups such as system L, y+L, −cx  (consisting of xCT 
and 4F2hc), asc, and b0,+. These transporters show some 
commonalities and differences in terms of binding affinity 
to different amino acid substrates. For example, alanine 
can be transported into the brain through systems L and/
or asc, which is an overlapped function between these 
transporters. For instance, system L plays a key role upon 
traverse of the neutral AAs (NAAs) in and out of the brain, 
maintaining desired concentrations of NAAs and hence 
affecting the NAA-related disorders such as depression. 
System L is a member of the gpaATs family, and possesses 
putative 12-transmembrane segment topology and 
comprises of light (LAT) and heavy (4F2hc) chains and 
two types of LAT1/4F2hc and LAT2/4F2hc.57 System L 
and other members of gpaATs including y+LAT1, y+LAT2 
and xCT share somewhat commonalities in terms of 
amino acid identity (around 40%-89%).
Furthermore, some of these transporters act as obligatory 
exchangers in an intricate holistic manner and play key 
roles in the mental health and neurological diseases 
through maintaining required concentrations. For 
example, xCT/4F2hc functions as the exchanger of 
L-cystine and L-glutamic acid.95 Of these amino acid 
transporters, system y+L functions as a Na+-dependent 
carrier for transportation of NAAs. Further, emergence 
of mutations in systems b0,+ and y+L transporters can 
respectively lead to cystinuria and lysinuric protein 
Table 1. ATP-binding cassette transporters’ functions and clinical significances
Family Members Function Clinical relevance 
ABCA Subgroup I: ABCA1, 2, 3, 4, 7, 12, and 13
Subgroup II: ABCA5, 6, 8, 9 and 10
Transportation of 
cholesterol and 
lipids 
Mutation in ABCA1 causes Tangier’s disease 
(hypoalphalipoproteinemia)35; Mutation in ABCA3 are 
associated to cataract-microcornea syndrome36 Mutation in 
ABCA4 causes autosomal-recessive disease Stargardt macular 
dystrophy (STGD)37; ABCA7 involves in Alzheimer's disease38; 
Mutation in ABCA5 cause excessive hair overgrowth39; 
Mutations in ABCA12 cause severe congenital skin disease 
harlequin ichthyosis40
ABCB ABCB1 (multidrug resistance protein 
1 (MDR1)/CD243, the so-called 
P-glycoprotein 1 (P-gp)
Export of divers 
xenobiotics and 
toxic metabolites 
P-gp transports various substrates across the BBB
ABCC ABCC also known as multidrug resistance 
proteins (MRPs) members are MRP1, 2, 3, 
4, 5, 6, 7, 8, 9, 10, 11, 12 and 13
Anions and 
conjugated 
metabolites (e.g., 
glucuronides, 
glutathione) efflux
Involved in ion transport, toxin secretion, and signal 
transduction at BBB (MRP1, 2, 4, 5, 6); Deficiency in 
functional expression of ABCC7 (CFTR protein) causes cystic 
fibrosis41; Overexpression of MRP2 at BBB contributes to 
drug resistance in epilepsy42; MRP4 involves in efflux of 
oseltamivir43
ABCD ABCD1 Transportation of 
long chain fatty 
acids
Mutations in ABCD1 cause accumulation of very long chain 
fatty acids; ABCD1 dysfunction at BBB contributes to the 
increased trafficking of leucocytes across the BBB as seen in 
cerebral adrenouleukodystrophy44
ABCE ABCE1 ABCE1 inhibits 
the action of 
ribonuclease L
Overexpression of ABCE1 promotes growth and inhibits 
apoptosis of tumor cells45
ABCF ABCF1 Export of some 
drugs
ABCF1 associates with Graves' ophthalmopathy46; ABCF1 may 
play a role in mediating antidepressant response47
ABCG ABCG1, 2, 3 and 4 Transportation of 
lipids, steroids, 
cholesterol and 
different drugs 
Loss of ABCG1/ABCG4 functions in the CNS alters metabolic 
pathways and elicits behavior changes48; Functional 
expression of ABCG2 at BBB results in markedly high efflux of 
divers drug substances49 
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intolerance that are considered as inevitable hereditary 
diseases.96 For example, two distinct genetic disorders, 
cystinura and Hartnup disease, are related to the sodium-
dependent neutral and basic amino acid transport protein 
rBAT (SLC3A1) and neutral amino acid transporter B0 
AT1 (SLC6A19).97-101 In regards to the sodium-dependency 
of the ABC transporters, System L, System y+ and System 
Xc– are further reviewed in the following sections.
System L
The system L functions as a Na+-independent bidirectional 
transporter that is responsible for both branched and 
aromatic neutral amino acids in almost all types of cells 
with different affinity to a range of large and small neutral 
amino acids.57,58,102,103 As shown in Table 3, LAT1 is a 
ubiquitous transporter with a high affinity for LNAAs and 
with Km values in the µM range, whereas LAT2 shows a 
lower affinity to LNAAs and higher affinity to SNAAs and 
possessing a Km value in the mM range for NAAs.58,102,104,105 
Fig. 5 represents the membrane topology model of 
glycoprotein-associated amino acid transporters (gpaATs, 
i.e., SLC7A5-11) including system L (LAT1/4F2hc 
and LAT2/4F2hc heterodimers).103 The heterodimeric 
complexation of 4F2hc with LAT1 or LAT2, through 
a covalent disulfide band, is in favor of functionality of 
the light chains and their co-expression as heterodimer 
complex - essential for transport functionality of the 
system. Table 2 represents AAs transporters whose 
associated heavy chain is the 4F2hc/rBAT.
In the absence of 4F2hc, the LAT1 is found in the 
intracellular compartments. Upon complexation with 
4F2hc, it can reach to the plasma membrane, while the 
4F2hc itself reaches the plasma membrane independently. 
The surface conformation of 4F2hc seems to be altered in 
the presence of LAT1, confining it to cell-cell adhesion 
sites. The 4F2hc comprises 529 amino acids (94 kDa, 
glycosylated; 72 kDa unglycosylated). The light chain 
LAT1 is widely expressed in non-epithelial cells including 
brain, spleen, thymus, testis, skin, liver, placenta, skeletal 
muscle, and stomach. 
In brain, LAT1 expression is found predominantly 
in capillary endothelial cells that form the BBB. In 
human, the LAT1 protein consists of 507 AAs with 
a molecular mass of 55 kDa, whose association with 
4F2hc (LAT1/4F2hc heterodimeric complex) induces 
transportation of LNAAs into the brain.58,106 Affinity 
of LAT1/4F2hc and LAT2/4F2hc transporters vary for 
different AAs. In addition to its role in neuronal cell 
proliferation (neurogenesis) in brain, system L shows 
affinity to thyroxin (T4) and triiodothyronine (T3). Table 
2 represents the Km values for some AAs in both subunits 
of the system L. Depending on the site of the biological 
membrane studied, luminal and abluminal transportation 
of AAs show different pattern. Since system L functions 
bi-directionally, the inward and outward traverses of AAs 
appear to differ one another, significantly. For example, the 
outward trafficking of L-phenylalanine seems to be greater 
than L-leucine whose inward transportation happens to 
be markedly high. A number of studies have shown that 
the subunits of system L (LAT1 and LAT2) act as an 
obligatory exchanger, so that the inward transportation 
of one AA may associate with the outward transportation 
of other AA.107 Such exchange functionality, which may 
be indirectly related to ATP-dependent transporters 
activities, seems to provide the driving force for the Na+-
independent AA transport systems including system L. 
Nevertheless, the molecular mechanism(s) of this process 
is yet to be fully understood. 
Of note, L-glutamine (Gln) is known as one of the 
most copious AAs in plasma and cerebrospinal fluid. 
It is a precursor for the CNS neurotransmitters such as 
gamma-aminobutyric acid (GABA). In an interesting 
study, Dolgodilina et al. analyzed the concentrations 
of Gln and also 13 other brain interstitial fluid AAs in 
mice by means of hippocampal microdialysis technique. 
Given that the interstitial fluid levels for all AAs 
including Gln were found to be approximately 5-10 
times lower than in cerebrospinal fluid, they showed 
that the competitive inhibition of systems L transporter 
by 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid 
(BCH) could significantly increase the concentration of 
Gln in interstitial fluid in comparison with inhibition of 
system A. They proposed an independent homeostatic 
regulation of AAs through system L transport machinery 
(LAT1/4F2hc) in the interstitial fluid in comparison with 
the cerebrospinal fluid.113 Since LAT1 is an important 
transporter for drug delivery into the brain through CMT 
machinery, Ylikangas et al. developed a comparative 
molecular field analysis (CoMFA) model for the guided 
synthesis of LAT1-specific novel prodrugs which were 
examined using an in situ rat brain perfusion technique. 
These researchers concluded that L-tryptophan (Trp) can 
be used as the promoiety for the creation of novel LAT1-
specific prodrugs with high-affinity.114 Likewise, in a 
Fig. 4. The modeled structure of GLUT1 as an ABC inward 
transporter. Panels A, B and C represent different modes of 
the protein with 12 transmembrane helices. Panel D shows the 
superimposed image of the space filling structure (panel A) and 
the ribbon style model (panel B). The visual molecular dynamics 
(freely available at: https://www-s.ks.uiuc.edu/Research/vmd/) 
was used to visualize the GLUT1 in different modes.81
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previous study, four phenylalanine derivatives of valproic 
acid were designed and examined for their potential to 
utilize the LAT1-mediated transportation. In this study, a 
novel meta-substituted phenylalanine analogue promoiety 
with high affinity to LAT1 was introduced – a proof of 
application for the LAT1-mediated brain targeting.115 In 
fact, despite ubiquitous expression of the LAT1 and LAT2 
transporters by BCECs, only a few drugs (e.g., L-DOPA, 
alpha-methyldopa, melphalan, and gabapentin) have been 
developed as the substrates of LAT1 and LAT2. This could 
be due to possible ambiguousness in the pharmacokinetics 
of LAT1 and LAT2 transporters because of involvement of 
other amino acid transporters.59,116 
Like any other AA transporters expressed by the BCECs, 
the impacts of system L transport machinery in healthy 
and diseased brain are yet to be fully elucidated. In fact, 
CNS disorders such as schizophrenia, depression and 
Parkinson appear to be largely dependent upon the 
brain uptake of LNAAs such as Trp and L-tyrosine (Tyr) 
through LAT1 and homeostasis of serotonin. Therefore, 
any malfunctioning of system L (e.g., mutations or other 
genetic defects) can affect the homeostasis of LNNAs 
that are precursors of various neurotransmitters. What 
is more, it seems that LAT1 and LAT2 functions are 
complementary, in which LAT2 can mediate the outward 
transportation of various AAs such as LNAAs that are 
not competently transported through the unidirectional 
transporter located in the same membrane. 
It appears that a complementary functioning transport 
systems such as y+LAT1 are involved in maintaining the 
Table 2. The glycoprotein-associated amino acid transporters at BBB
Transporter 
system
Light chain 
subunit
Heavy 
chain 
subunit
Tissue/
Localization
Function
Transport type
Pathology
Influx Efflux
L LAT1 
(SLC7A5)
4F2/CD98
(SLC3A2)
Ubiquitous: 
ovary, placenta, 
brain>spleen, 
testis; activated 
lymphocytes; 
some tumor cells
L-type AAT 1; Na+-
independent, prefers 
L over A, accepts 
BCH, functions as an 
exchanger
L,H,I,F,Y,W,
V,(M,Q)
L, others 
n.d.
n.d.
LAT2 
(SLC7A8)
4F2/CD98
(SLC3A2)
Kidney proximal 
tubule, small 
intestine>>ovary, 
placenta, brain 
L-type AAT 2; higher 
affinity to small 
NAAs (e.g. A) than 
LAT1, functions 
as an exchanger; 
basolateral in 
transporting epithelia
F,Y,W>T,I,C,S,V,L,Q,
A,H,N,M>(G)
F,I,L,
others
n.d.
n.d.
y+ L y+LAT1 
(SLC7A7)
4F2/CD98
(SLC3A2)
Kidney, small 
intestine, 
leukocytes, lung, 
erythrocytes, 
placenta/ 
basolateral, brain 
Na+-dependent large 
NAAs/ dibasic AAs 
exchanger
Na+-dependent: 
L,Q,M,H0, (A,F); 
Na+-independent: 
(R,K,H+)
R, no L, 
others 
n.d.
Lysinuric 
protein 
intolerance 
(y+LAT1)
Y+LAT2 
(SLC7A6)
4F2/CD98
(SLC3A2)
Brain (glia, 
neurons), small 
intestine, testis, 
parotis, heart, 
kidney, lung, liver/ 
basolateral
Na+-dependent 
NAAs/dibasic 
AAs exchanger; 
glutamine/arginine 
exchanger
similar to y+LAT1 n.d. n.d.
X-c xCT 
(SLC7A11)
4F2/CD98
(SLC3A2)
Macrophages, 
liver, kidney, brain, 
retinal pigment 
cells/basolateral
Glutamate/cystine 
exchanger 
C-C>E E n.d.
asc ascAT1
(SLC7A10)
4F2/CD98
(SLC3A2)
Brain, lung, 
placenta, small 
intestine, kidney/
basolateral
Na+-independent 
exchanger of small 
NAAs, also D-serine, 
D-glycine
A,G n.d. n.d.
B0,+ b0,1AT
(SLC7A9) 
rBAT
(SLC3A1) 
Kidney, small 
intestine, brain/
apical
Na+-independent 
exchanger of neutral/
dibasic AAs; cystine, 
arginine, lysine, 
and ornithine 
reabsorption
C-C,R,K,>L,Y,A L,R,A 
other n.d.
Cystinuria 
type I 
(rBAT) and 
non-type I 
(b0,1AT) 
The gene name for each transport system is presented in the bracket. The capital single letter identity was used to present amino acids. 
C-C: L-cystine; H+: the protonated L-histidine; H0: the zwitterionic form of L-histidine. AAs: amino acids; AAT: amino acid transporter; 
NAAs: neutral amino acids; diAAs: diamino acids; n.d.: not determined. For detailed information, readers are referred to the following cited 
articles.91-94
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CNS homeostasis from AA concentration viewpoints.112 
Further, on the ground of anomalous overexpression of 
the LAT1 on the membrane of different types of cancerous 
cells,117-121 this transporter is considered as a potential 
cancer marker molecule for targeted therapy.122-124 For 
example, qRT-PCR and Western blot analyses of the 
expression of three cancer-associated CMTs involved in 
the traverse of AAs (i.e., LAT1, ASCT2 and SN2) have 
revealed that the LAT1 was markedly upregulated in 
human ovarian cancer cells (SKOV3, IGROV1, A2780, 
and OVCAR3 cell lines as compared to the normal 
ovarian epithelial IOSE397 cells), whereas the functional 
expression of ASCT2 and SN2 transporters was not 
altered.117 Therefore, the LAT1 has been considered as a 
target for the combinational therapy of cancer using anti-
proliferative agents such as aminopeptidase inhibitors. 
In 2015, Wu et al. developed a LAT1-mediated 
chemotherapeutic agent using aspartate-conjugated 
doxorubicin (Asp-DOX) with high affinity to LAT1. These 
researchers showed that the Asp-DOX could substantially 
inhibit the LAT1 overexpressing cancer cells. Such 
findings were further confirmed by pharmacokinetic data 
through significant accumulation of Asp-DOX within the 
tumor tissue in HepG2 and HCT116 tumor-bearing mice 
most likely through LAT1 uptake. Upon which, the Asp-
DOX was proposed as a new treatment strategy for the 
LAT1 overexpressing cancer cells.124 
Owing to high expression of the LAT1 at the BBB, prodrugs 
can be developed to mimic the AAs that are substrates 
of LAT1. These prodrugs should ideally possess both 
the negatively charged alpha-carboxyl and the positively 
charged alpha-amino groups.125 
System y+
Transportation of cationic amino acids (CAAs) is 
mediated through two families of proteins that are 
abundant in different cells/tissues. These families are (a) 
system y+ so-called CAA transporters (CAT), and (b) 
broad-scope amino acid transporters (BAT) consisting of 
systems b0,+, B0,+, and y+L. The functional expression 
and distribution of CATs and BATs by BCECs have not 
been fully addressed. Plasma membranes of bovine brain 
microvessels have been isolated and used to identify the 
CAAs transporters at BBB; as a result, the system y+ was 
found to be the only transporter present, mostly on the 
abluminal membrane. It showed voltage dependency 
and K M values at µM range for AAs such as L-lysine, 
L-arginine, and L-ornithine. The system y+, in the 
presence of Na+, was inhibited by several essential neutral 
AAs with Ki values of 3-10 times greater than the plasma 
concentrations. However, some small nonessential AAs 
(i.e., serine, glutamine, alanine, and glycine) were able to 
inhibit the system y+ with Ki values similar to their plasma 
concentrations, implying that the system y+ might be 
involved in BBB traverse of these AAs. Further, the system 
y+ could be a key transporter in traverse of arginine that is 
necessary for the synthesis of nitric oxide (NO) in cerebral 
endothelial cells.63 Taken all, it seems that this system is the 
only CAA transport machineries at BBB.63,64 It should be 
also stated that y+LAT1 (SLC7A7) is highly expressed at 
the basolateral membrane of epithelial cells in the intestine 
and kidney. It is involved in transportation of dibasic 
AAs, and emergence of mutations in this transporter 
can lead to lysinuric protein intolerance (LPI). It is an 
inherited aminoaciduria that is a rare recessive disorder 
Fig. 5. Predicted membrane topology of the glycoprotein-associated amino acid transporters (gpaATs) in association with type II surface 
glycoprotein (4F2hc/CD98 or rBAT/ D2). Panels A, B and C represent 3D models of LAT1 (SLC7A5), 4F2hc (SLC3A2) and their interacted 
structures, respectively. Panel D shows the assumed interaction of gpaATs and CD98/D2 with cell membrane. The conserved regions of 
gpaATs are drawn as red color. The amino acids (AAs) of the aligned sequences (human and mouse LAT1, LAT2 and y+LAT1; human 
y+LAT2; mouse xCT; human, rat, mouse and rabbit b0,+AT) show some commonalities and differences. There are some AAs that are 
not present in all aligned sequences. Numbers 1-12 show the predicted position of the putative transmembrane helices. The two-third 
predicted transmembrane segments could take an α-helical structure. For function of gpaATs, they need to be coupled with their related 
heavy chain (4F2hc/rBAT). As showed in panel D; gpaATs have an intramolecular covalent disulfide bridge (S–S) with their associated type 
II glycoprotein. Human rBAT and 4F2hc have six and three possible N-glycosylation sites, respectively. For detailed information, readers 
are referred to the following cited articles.91 I-TASSER web-server has been utilized for homology modeling of this complex protein. 
Transmembrane sections were also identified by use of UniProt detailed annotations (http://www.uniprot.org/). The UCSF Chimera v1.11 
standalone software (freely available at: http://www.rbvi.ucsf.edu/chimera) and Visual Molecular Dynamics (VMD) (freely available at: 
https://www-s.ks.uiuc.edu/Research/vmd/) were used for visualization of LAT1/4F2hc.81 Note: Not drawn/modeled to scale.
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with certain symptoms such as growth retardation, 
muscle hypotonia and hepatosplenomegaly. Technically, 
LPI patients are compound heterozygote with a missense 
mutation(s) in one allele and a frameshift mutation in 
the other.126,127 Defective functionality of the y+LAT1 was 
reported to be influential on the functional expression 
of y+LAT2 (SLC7A6), perhaps through interference 
with its compensatory functions in LPI patients.128 The 
pathological consequences of such mutations at the BBB 
are yet to be fully understood. 
System Xc–
As an ABC transporter the system Xc– (SLC7A11) 
possess 12 transmembrane helices and extracellular and 
cytoplasmic domains (Fig. 6). It is critical in AA exchanger 
function in various cell types such as BCECs.
Given the importance of glutathione (GSH) inside and 
outside of the CNS, several mechanisms are involved in 
its regulation, including Nrf2-ARE signaling pathway.129 
Further, the synthesis of GSH is attributed to some enzymes 
as well as CMTs such as system Xc– and excitatory amino 
acid transporters (EAATs) such as EAAT1, 2 and 3.130 
Fig. 7 represents the inward and outward trafficking 
of L-cysteine and L-glutamine by the brain capillary 
endothelial cells. At the BBB, the endothelial cells 
functionally express the EAATs on the abluminal 
membrane to shift the glutamate molecules from the 
extracellular fluid (ECF). This function controls the 
traverse of glutamate molecules in the CNS, resulting in 
selective maintenance of the low glutamate concentrations 
in the ECF within the CNS. As a result, the BBB remains 
almost impermeable to L-glutamate even at high 
concentrations. However, some diseases (e.g., diabetes131) 
can compromise the integrity of BBB.132 It should be 
noted that the excessive amounts of glutamate can result 
in toxic impacts in the neurons, while the EAATs in 
cooperation with system Xc– recycle the extra amount 
through efflux and production of GSH. Based upon 
the glutamate-glutamine cycle, the neurotransmitter 
glutamate is adequately maintained in the CNS, where the 
neurons are not able to synthesize the neurotransmitter 
as well as the γ-aminobutyric acid (GABA) from glucose. 
There is a glutamate-glutamine cycle between neurons 
and astrocytes, at which the liberated glutamate/GABA 
Table 3. Affinity of system L transporters to different amino acids and drug/chemical substances
Amino acid
Affinity (KM value) Condition/model Ref.LAT1/4F2hc LAT2/4F2hc
Thyroxin (T4) 7.9 µM − Xenopus laevis oocyte and presence of choline 
chloride
108
Triiodothyronine (T3) 0.8 µM − Xenopus laevis oocyte and presence of choline 
chloride
108
Reverse triiodothyronine (rT3) 12.5 µM − Xenopus laevis oocyte and presence of choline 
chloride
108
3,3'-diiodothyronine (T2) 7.9 µM − Xenopus laevis oocyte and presence of choline 
chloride
108
L-Phenylalanine 14.2 µM 45.0 µM Xenopus oocyte 109, 110
55.2 µM − T24 human bladder carcinoma cells 104
L-Isoleucine 25.1 µM 96.7 µM Xenopus oocyte 109, 110
L-Methionine 20.2 µM 204.0 µM Xenopus oocyte 109, 110
L-Valine 47.2 µM 124.0 µM Xenopus oocyte 109, 110
L-Histidine 12.7 µM 181.0 µM Xenopus oocyte 109, 110
L-Tyrosine 28.3 µM 35.9 µM Xenopus oocyte 109, 110
60.4 µM − T24 human bladder carcinoma cells 104
16.4 µM − Human fibroblasts 111
L-Leucine 19.7 µM 151.0 µM Xenopus oocyte 112
L-Tryptophan 21.4 µM 57.6 µM Xenopus oocyte 109, 110
L-Asparagine 1.6 mM 80.7 µM Xenopus oocyte 109, 110
L-Glutamine 2.2 mM 275.0 µM Xenopus oocyte 109, 110
L-Threonine − 68.6 µM Xenopus oocyte 110
L-Alanine 10.0 mM 978.0 µM Xenopus oocyte 110
L-Glycine − 265.0 µM Xenopus oocyte 110
L-Serine − 116.0 µM Xenopus oocyte 110
L-Dopa 34.2 µM − T24 human bladder carcinoma cells 104
3-O-Methyldopa 96.5 µM − T24 human bladder carcinoma cells 104
α-Methyltyrosine 153.0 µM − T24 human bladder carcinoma cells 104
α-Methyldopa 216.0 µM − T24 human bladder carcinoma cells 104
Gabapentin 191.0 µM − T24 human bladder carcinoma cells 104
Melphalan 73.5 µM − T24 human bladder carcinoma cells 104
BCH 156.0 µM T24 human bladder carcinoma cells 104
For detailed information, readers are also referred to the cited articles. BCH: 2-Aminobicyclo-[2, 2,1]heptane-2-carboxylic acid.
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molecules from neurons can be taken up by the astrocytes 
that are able to convert it to glutamine.133 The latter 
biomolecules can be used by neurons as precursors for 
the synthesis of glutamate or GABA. However, in the case 
of ischemic brain damages, the EAATs function reversely 
resulting in the accumulation of glutamate molecules in 
the ECF and hence the blockage of neurotransmission. At 
the BBB, the system Xc– pumps the glutamine molecules 
out of the ECF of CNS into the endothelial cells and then 
to the blood. Further, the BCECS are also able to hydrolyze 
glutamine, and use it for production of GSH. In such 
process, harmonically orchestrated functions of various 
AA transport machineries such as Na+-dependent systems 
N (astrocytes) and A (neurons) as well as facilitative 
glutamate transporters maintain such homeostasis.133 
The role of BBB and transportation of glutamate has 
comprehensively been discussed recently, readers are 
referred to the cited article.132 
Nucleoside trafficking 
Trafficking of nucleosides and related anticancer and 
antiviral nucleoside drugs across the BBB is mediated 
through the nucleoside transporters (NTs) located on 
the plasma membrane of the BCECs. These transport 
machineries play pivotal role in maintaining the 
homeostasis of the nucleosides within the CNS, in 
particular the level of adenosine, to keep it available to 
bind to receptors, by which a variety of physiological 
processes are modulated.134 
It should be stated that S-(4-Nitrobenzyl)-6-thioinosine 
(NBTI, NBMPR) riboside has been used for determination 
of the equilibrative nucleoside transport processes in 
mammalian cells, upon which these transporters are 
categorized into the NBMPR-sensitive (es) or NBMPR-
insensitive (ei).135 Previously, Chishty et al. aimed at 
examining the functional expression of CMT subtypes 
involved in the nucleoside transfer between blood and 
brain employing the RBE4 immortalized rat brain 
endothelial cells. Their findings revealed that the uptake 
of nucleosides by these cells was partially sodium 
dependent, which indicated that transportation occur 
in both equilibrative and concentrative manners. While 
these researchers reported that the uptake of adenosine via 
equilibrative transporter(s) are sensitive to NBMPR, they 
also showed the involvement of concentrative transporters 
in the uptake of adenosine which was significantly 
inhibited by subtype-specific inhibitors thymidine (cit) 
and formycin-B (cif), but not tubercidin (cib).136 A number 
of studies have disclosed involvement of two major families 
Fig. 6. Three-dimensional structure of ATP-binding cassette 
transporter, system Xc–. The Na+-independent system Xc– 
functions as L-cysteine/L-glutamate antiporter. Panel A shows 
an active site (Glu309) and N-glycosylation residue (Asn314). 
Panels B, C and D show the ligand binding site residues (Thr56, 
Ile57, Ala60, Gly61, Ile133, Ile134, Ala137, Ala138, Val141, 
Tyr244, Ala245, Tyr246, Ala247, Gly334, and Lue392) from 
different prospects. The positive and negative charged amino 
acids, α-helix and coil regions of the model are also indicated. The 
structure is modeled through I-TASSER web server and based on 
threading and homology modeling approaches and is visualized 
by UCSF Chimera v1.11 software (our unpublished data).
Fig. 7. Inward and outward trafficking of L-cysteine and 
L-glutamine by the brain capillary endothelial cells. System Xc– 
acts as the exchanger for amino acids such as L-cysteine and 
L-glutamine, and in close cooperation with excitatory amino acid 
transporters (EAATs) traverse of glutamate is controlled by its 
efflux from brain and production of glutathione. Glutamate as the 
most abundant excitatory neurotransmitter can be transported 
among brain capillary endothelial cells, neurons and astrocytes, 
where the endothelial cells of the blood-brain barrier play pivotal 
role in maintenance of glutamate in brain. Glutamate is stored in 
vesicles at the chemical synapses, where the impulses of nerve 
is able to activate the liberation of the glutamate molecules from 
the presynaptic cell. Its concentration in the extracellular space 
is controlled through Na+-dependent glutamate transporters 
(i.e., EAAT1, 2 or 3) found in neuronal and glial membranes. Any 
malfunctioning of EAATs may result in inadvertent accumulation 
of glutamate molecules causing inevitable excitotoxicity and 
interfering with the normal activity of neurons (our unpublished 
data). Note: Not drawn to scale. 
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of membrane NTs, including (a) equilibrative nucleoside 
transporters (ENTs) and (b) concentrative nucleoside 
transporters (CNTs). ENTs transport nucleosides in a 
gradient-dependent fashion, while the CNTs import 
nucleosides against a gradient by coupling movement 
with sodium transport.137 The ENT family consists of two 
subtype proteins in human cells (hENT1/SLC29A1 and 
hENT2/SLC29A2) that are involved in the transportation 
of purine and pyrimidine nucleosides down their 
concentration gradients. The human ENTs are either es 
(hENT1 with KM values of 0.62 mM for adenosine) or ei 
(hENT2 with KM values of 0.75 mM for adenosine and 0.2 
mM for uridine).135,138 Of the six functional subtypes of 
human CNTs, three of them (hCNT1/SLC28A1, hCNT2/
SLC28A2 and hCNT3/SLC28A3) are considered as well-
characterized Na+–linked nucleoside cotransporters that 
are concentrative, insensitive to NBMPR and accept 
permeants.139 These transporters act selectively, in which 
the hCNT1 (system cit) and the hCNT2 (system cif) 
transport respectively pyrimidine and purine nucleosides, 
while the hCNT3 (system cib) is involved in transportation 
of both pyrimidine and purine nucleoside.140 The hCNT1 
exhibits the transport properties of the NT system cit 
or N2 subtype (N2/cit) that is selective for pyrimidine 
nucleosides and adenosine. It is able to transport the 
antiviral pyrimidine nucleoside analogs 3’-azido-3’-
deoxythymidine (AZT) and 2’,3’-dideoxycytidine (ddC), 
while shows different affinity to nucleosides. The hCNT2 
shows the transport characteristics of the NT system cif or 
N1 subtype (N1/cif) that is selective for purine nucleosides 
and uridine. The hCNT3 exhibits the transport features of 
the NT system cib or N3 subtype (N3/cib) that is selective 
for transportation of cytidine (KM= 15.4 µM) thymidine 
(KM= 21.2 µM), uridine (KM= 21.6 µM), adenosine (KM= 
15.1 µM), guanosine (KM= 43.0 µM) and inosine (KM= 
52.5 µM),140,141 as well as gemcitabine, AZT, ribavirin and 
3-deazauridine.140 
Recently, Lepist et al. studied the transportation of 
tecadenoson, which is a selective A1 adenosine receptor 
agonist with similar structure to that of adenosine, into 
the CNS. Based on their findings, the binding affinities 
of the hENTs and hCNTs to tecadenoson largely varied 
showing the following pattern: hENT1 > hCNT1 > hCNT3 
> hENT2 > hCNT2. They concluded that the hENT1 is 
the main transporter of the tecadenoson at the BBB.142 
In fact, the hENT1 is a ubiquitous transporter found in 
various human cells/tissues. The hENT2 is expressed in 
a variety of tissues such as the skeletal muscle where it 
plays a predominant role. Its functional expression in the 
brain microvasculature endothelial cells is yet to be fully 
addressed. 
It should be highlighted that both pyrimidine and 
purine nucleoside analogs are currently used in clinic. 
Accordingly, various prodrugs can be developed to mimic 
these transporters capacities.143,144 Of the pyrimidin 
analog drugs used in clinics, cytarabine (Cytosar-U®, 
Ara-C, DepoCyt®) is an analog of deoxycytidine (1-β-d-
arabinofuranosylcytosine). It is used in the combination 
chemotherapy against chronic myelogenous, leukemia, 
multiple myeloma, Hodgkin’s lymphoma and non-
Hodgkin’s lymphomas. Gemcitabine (Gemzar®, Eli Lilly 
and Company, USA) has broad spectra applications in 
treatment of various malignancies such as pancreatic 
and bladder cancers. Capecitabine (Xeloda®, Roche, 
Switzerland) is a prodrug and analog of pyrimidin used 
orally for the treatment of metastatic gastric, colorectal, 
oesophageal and breast cancers. Of the purine nucleoside 
analogs, fludarabine (Fludara®) is used for the treatment 
of low-grade lymphomas. Cladribine (Leustatin®) is used 
for the treatment of hairy cell leukemia and for B-cell 
chronic lymphocytic leukemia. 
Efflux CMTs
In addition to influx systems of CMTs at the BBB, brain 
capillary microvasculature embraces some key transport 
machineries that act as major hindrance against the entry 
of a number of different therapeutic drugs into the brain 
parenchyma – a function known as the efflux pumps of 
BBB. Of these, multidrug resistance 1 (MDR1/ABCB1)/
P-gp as an ATP-binding cassette (ABC) drug transport 
protein seems to be the major efflux system at BBB that 
is predominantly found in the luminal sides of different 
endothelial and epithelial cells as well as polarized 
BCECs.145,146 The putative transmembrane biostructure 
of human MDR1/P-gp is primarily found in the plasma 
membrane cell as 12 transmembrane segments that 
form a three-dimensional structure in the cell plasma 
membrane blocking the entry of various compounds. This 
polypeptide consists of two similar halves with six putative 
transmembrane segments and intracellular ATP-binding 
site (Fig. 3B, C). The hydrolysis of ATP biomolecules 
appears to maintain the active export of substrates by this 
transporter. 
It has been shown that mouse and human P-gp transporters 
are able to actively export a number of compounds such 
as ivermectin, dexamethasone, digoxin, cyclosporin 
A and morphine across the polarized epithelial cells 
in vitro. In wild-type mice, the efflux of digoxin and 
cyclosporine was 20- to 50-fold higher than that of the 
mdr1a knockout mice.147 Of the ABC transporters, in 
addition to MDR1/P-gp, the MRPs and cancer resistance 
protein (BCRP) expressed by BCECs can also pump out 
a large number of various compounds.7 For example, 
it has recently been shown that both HIV-1 protease 
inhibitors (HPIs) and nucleoside reverse transcriptase 
inhibitors (NRTIs) are prone to be taken out by the 
efflux function of BBB through MRPs (e.g., MRP1 and 
MRP2).148 Further, it has also been reported that the brain 
accumulation of sunitinib, as a multi-targeted tyrosine 
kinase inhibitor (TKI), is markedly restricted by both 
ABCB1 and ABCG2 efflux activities. Given that the full 
inhibition of these transporters can significantly increase 
the accumulation of sunitinib within the brain, combined 
oral administration of sunitinib with the P-gp inhibitor 
elacridar can be of great benefit in treatment of brain 
tumors.149 While sunitinib is metabolized by CYP3A4, 
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perhaps rationalized combination of the CYP3A4 
inhibitor (ritonavir) to such combination therapy could 
augment the impacts of pharmacotherapy, an extended 
exposure of BCECs to ritonavir was reported to impose 
a concentration-dependent increase in P-gp activity and 
expression. It has been shown that cyclosporin A (CysA) 
as a potent P-gp and MRP modulator, is able to moderate 
the concentration of methotrexate (MTX) in the rat brain. 
As a result, it is proposed as a useful tool to achieve an 
appropriate MTX concentration in brain in the case of 
brain tumors.150 As another instance, it has been shown 
that antiepileptic drugs (AEDs) can only treat 30-40% of 
patients with epilepsy effectively. Such failure is deemed 
to be in large part due to the impacts of efflux functions 
of BCECs on outward transportation of AEDs which may 
be considered as a mechanism for resistance to AEDs in 
epileptic patients.151 Of the AEDs, lacosamide (LCM) has 
been tested for its liability towards efflux functions in cell 
models by concentration equilibrium transport assays 
(CETAs). In addition, LCM can be taken up by MDR1 
expressing cells through a passive diffusion, however it 
could be a substrate of P-gp in CETA.151
Peptide transporters
Peptides (mostly di-/tri-peptides) are normally crossed 
the BBB through peptide transporters found as an 
integral part of the plasma membrane proteins which 
also mediate the trafficking of peptide-mimetic drugs. It 
should be noted that the electrochemical Na+ gradient, 
the so-called sodium-motive force (SMF) is the main 
driving force for the active/facilitated transportations of 
a variety of biomolecules such as AAs and carbohydrates 
in the most of living cells as well as the mammalian cells. 
The peptide transport process, nevertheless, seems to be 
an evolutionary shift in the coupling ion and favors H+, 
through which a proton-motive force (PMF) energizes 
active traverse of peptides through cell membrane. 
Interestingly, various cellular transportation activities 
in mammalian cells are coupled with the Na+/H+ 
exchangers (NHEs), Na+/K+ pump and H+ pump in terms 
of energy transduction.152,153 Regulation of these cellular 
machineries orchestrate the solutes concentrations within 
the cells as well as the ECF, playing central roles in health 
and diseases. For example, in addition to the key role of 
NHE1 (SLC9A1) in dysregulation of pH in the tumor 
microenvironment (TME),89 ischemia-reperfusion was 
shown to induce cardiac injuries that are mediated by 
NHE1. Its upregulation can modulate the activity of the 
plasmalemmal Na+/Ca2+ exchanger.152 While NHE1 and 
NHE2 (SLC9A2) are the keystones in maintaining the 
volume and ionic compositions of brain interstitial fluid,154 
their roles in brain ischemic disease can be expected.155 
Up until now, two peptide transporters, namely PepT1 
(SLC15A1) and PepT2 (SLC15A2), have been discovered in 
human, which are known as proton-coupled transporters 
that influx oligopeptides of 2 to 4 AAs. Although their 
distributions vary from one organ to another, they are 
markedly expressed by the epithelia of intestine and kidney 
mediating critical physiologic functions – important for 
the cellular homeostasis of peptides and AAs. PepT1 
seems to be a key transporter in the intestine for overall 
AAs/peptide absorption only after high dietary protein 
intake.156 Importantly, in the renal proximal tubule, there 
exist active transport mechanism(s) for small peptides, 
which are responsible for conserving the peptide-bound 
amino nitrogen otherwise it can be excreted through the 
urine. Further, the activity of these transporters seems to 
be orchestrated with the functionalities of the low-affinity 
peptide transporters in the lysosomes. This may indicate 
that the digestion and absorption of the dietary proteins 
and also peptidomimetic drugs may not be complete by 
intralysosomal digestion of proteins within intestine. Thus, 
the cellular digestion of peptides continue to generate free 
AAs and small peptides by the lysosomes, which display 
some other transporters such as AA transport systems in 
the lysosomal membrane. Similarly, some evidences have 
been reported upon the selective transport of di- and tri-
peptides across the lysosomal membrane.157,158 It should 
be also highlighted that the endoplasmic reticulum (ER) 
carries a transport mechanism for peptides in antigen-
presenting cells. This is done by the functional expression 
of transporter associated with antigen presentation (TAP), 
where TAP1 and TAP2 build a functional heterodimer 
that mediates the translocation of the peptides across the 
ER.159,160
PepT1 can be used for peptidomimetic oral drug delivery 
through intestine.161 Accordingly, the bioavailability 
of prodrugs specific to PepT1 was shown to be higher 
than those of the corresponding parent compounds, 
in large part because of the improved transportation. 
Such phenomenon have emerged a new field of peptide 
transporter mediated targeted therapy, so-called PepT1-
targeted prodrugs.162 Valganciclovir, a valyl ester of 
ganciclovir, was clinically shown to possess markedly 
higher bioavailability than ganciclovir when taken orally 
by patients with cytomegalovirus infection, in large part for 
being substrate of both PepT1 and PepT2.163 A number of 
drugs seem to be substrate to these transporters, including 
amoxicillin, benazepril, captopril, cefixime, cephalexin, 
enalapril, levodopa, oxacillin, Ramipril, tolbutamide and 
valaciclovir. They are relatively stereoselective, while 
showing greater affinity to the peptides formed from L 
isomer amino acids than those possess D isomer amino 
acids. Kinetically, depending upon the substrate, PepT1 
is considered as a low-affinity and high-capacity system 
which yields apparent affinity constants, Km, ranging from 
0.2-10 mM. However, PepT2 is also considered as a high-
affinity and low-capacity transport system showing Km 
values of 5–500 μM. 
Endocytosis, transcytosis and RMTs
Cellular trafficking of macromolecular biomolecules is 
mediated through membranous vesicular machineries 
that are comprised of numerous components including 
lipid rafts, membranous caveolae and CCPs/clathrin-
coated vesicles (CCVs). Various cell micro-/nano-
BBB transporters and targeted therapy of brain diseases
BioImpacts, 2016, 6(4), 225-248 237
machineries are involved in vesicular trafficking, 
including Rab GTPases. Of various Rab family of proteins 
as a member of the Ras superfamily of monomeric G 
proteins, different Rab GTPases are responsible for 
regulation of different processes of the membrane 
trafficking such as the formation and travelling of vesicles 
within the cytoskeleton’s actin and tubulin networks 
and even invagination and fusion processes. The newly 
biosynthesized protein in ER is trafficked across the Golgi 
(cis, medial and trans sections) to be matured and reach to 
other cell compartments or outwardly to the ECF through 
exocytosis, during which Rab GTPases play key roles. 
Fig. 8 shows schematic representation for the vesicular 
trafficking.
The cellular machineries involved in transportation of 
macromolecular biomolecules vary depending on the 
nature of the cargos and their interaction with plasma 
membrane. Endocytic internalization follows either 
nonspecific routes or specific mechanisms. Of the 
nonspecific endocytosis, the fluid-phase endocytosis (the 
so-called pinocytosis) is responsible for internalization of 
solutes that are present within the ECF bathing the plasma 
membrane, during which the plasma membrane encircle 
the surrounding solutes in the ECF and internalize them 
through the lumen of the budding vesicles. Classic fluid-
phase markers include horseradish peroxidase (HRP) and 
dextrans.164 In the case of nonspecific interaction of solutes 
through non-specific mechanisms such as electrostatic 
interactions, they are internalized by adsorptive 
endocytosis. Positively charged substances (e.g., cationic 
lipids, polymers, dendrimers, nanoparticles, and albumin) 
are able to interact with the cell surfaces that are negatively 
charged and internalize through the adsorptive endocytic 
path.166-171
The specific endocytic path is entirely dependent upon the 
receptor–ligand pairing process, in which solute molecules 
bind to its cognate receptor on the cell membrane. Once 
paired with the canonical receptor, solute are internalized 
into the cytoplasm through either a constitutive (class I) 
or ligand-stimulated (class II) internalization processes.164 
In the constitutive endocytosis, the continual plasma 
membrane turnover with the receptor internalized in an 
endocytic vesicle mediates the endocytosis process in the 
presence or even absence of the ligands such as Tf or LDL. 
In the ligand-stimulated endocytosis, the ligand-receptor 
pairing process is the main driving force for the initiation 
of the internalization of the ligands such as insulin and 
epidermal growth factors (EGFs). 
In the RMTs, several key receptors are specifically 
responsible for the transportation of various biomolecules 
including insulin, insulin-like growth factor, leptin Tf and 
LDL. 
Endosomal trafficking
Vesicles, after reacting into the cytoplasm, must be sorted 
out and directed to their specific itinerary. As a result, 
in a short period of time (<10 min), the internalized 
vesicles fuse with the early endosomes that act as an 
initial sorting station and express molecular markers 
such as the early endosome antigen-1 (EEA-1). In the 
early endosomes, where the pH is acidic (<pH 6.0), the 
transported cargo molecules dissociate from their specific 
receptors. This process is essential step for transportation 
of ligands to lysosomes for their degradation. The acidic 
condition of lysosomes enhances the binding affinity of 
IgG molecules in attaching to the neonatal Fc receptors 
(FcRns) that are expressed by variety of cells in particular 
endothelial cells such as BCECs,172 and rescue the IgG 
molecules from degradation.164 In polarized cells such as 
BCECs, the endocytic activities occur both in luminal and 
abluminal sections with distinct specifications that is in 
favor of either blood-to-brain or brain-to-blood traverse 
of substances, depending on biological prerequisites and 
activities of the brain cells. Such process also favors the 
recycling process of the endocytosed receptors, which 
allow cells to constantly recycle the receptor and dispose 
them back in the original membrane, unless they possess 
necessary signals for degradation or transcytosis. For 
example, the epidermal growth factor and its cognate 
receptor (EGF-EGFR) complex is basically trafficked 
to the lysosomes to be destructed, while other ligand-
receptor pairs may possess signals for transcytosis. 
Trafficking of albumin following binding to its cognate 
receptor gp60 results in transcytosis of albumin.173,174 
FcRn-IgG complex undergoes transcytosis at the BBB in 
both directions, i.e., apical-to-basal (A-to-B) and basal-
to-apical (B-to-A).175 The B-to-A transportation (the so-
called reverse transcytosis) of IgG molecules seems to 
depict the efflux of therapeutic immunotherapies from 
CNS in rat brain,176 resulting in failure of the treatment 
modalities in CNS diseases. It is now clear that FcRn play 
a critical role in controlling IgG pharmacokinetics as well 
as serum albumin trafficking,177 by which the improved 
pharmacokinetics of albumin-conjugated therapeutics can 
be explicated. In a study, to investigate the FcRn impact of 
the efflux of Abs, Cooper et al. treated rats with two mAbs 
specific to FcRn with markedly different binding affinities 
(IgG1 N434A and H435A) by intra-nasal-to-CNS and 
intra-cranial administrations. Upon intra-nasal delivery, 
mAbs reached the low cerebral hemisphere within 20 min, 
where the Ab with higher affinity to FcRn (N434A) showed 
a faster clearance trend. Having bilateral injection into the 
rat cortex, decreased and increased levels of N434A was 
detected respectively in the cerebral hemispheres and in 
serum, indicating the profound role of FcRn in efflux of 
IgG from the rat brain.176
In tack of selective retrieval of the endocytosed 
substances, they undergo further vesicular trafficking 
towards the late endosomes that are multivesicular 
bodies enriched in lysobisphosphatidic acid and others 
in phosphatidylinositol 3-phosphate (pH, 5.5–6.0) and 
potential to have homotypic/heterotypic fusion with 
lysosomes.178 This is a process by which the endocytosed 
cargo molecules undergo the proteolytic degradation by 
lysosomes (pH, 5.0) that is known by the expression of 
the lysosome associated membrane protein-1. Once in the 
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lysosome, the endocytosed molecules are exposed to array 
of hydrolytic enzymes such as proteases, lipases nucleases, 
glycosidases and phospholipases.179-181 
For the endosomal trafficking, RMT follows different 
routes such as membranous caveolae, CCPs and lipid rafts 
that will be further discussed.
Caveolae-mediated endocytosis
Membranous caveolae are flask-shaped invaginations of 
the plasma membrane is described as “smooth” vesicles 
with sizes ranging from 50 to 100 nm and coated by a 22 
kDa structural protein caveolin, whose N and C termini 
remain cytoplasmic.182 Initially detected in endothelial 
cells, caveolae tend to mediate the selective uptake of 
various small molecules and macromolecules such as 
albumin and lipoproteins. Functional expression of 
caveolin is linked with the maintenance of health and 
progression of various diseases such as cancers, hence it 
is considered as a new molecular marker for the targeted 
therapy of related diseases.183,184 Caveolae has initially 
been detected in endothelial cells and is highly enriched 
in biomolecules such as glycosphingolipids, cholesterol, 
sphingomyelin, and lipid-anchored membrane proteins. 
Of these biomolecules, cholesterol plays a crucial role of in 
the biogenesis of caveolae. It has been validated by treating 
cells with cholesterol binding agents (e.g., nystatin, filipin, 
or cyclodextrin). This results in obliteration of caveolae 
structures. Further, the subcellular transition of the main 
protein of caveolae vesicles, caveolin, is intricately linked 
to the transportation of cholesterol. Given the fact that 
cholesterol is predominantly transported to the plasma 
membrane through a Golgi-independent vesicular 
Fig. 8. Schematic representation for the diversity of vesicular internalization and trafficking. Macromolecular entities (e.g., bacteria, 
viruses) can be internalized through phagocytosis (I). Engulfed particles within the phagosomes are prone to fusion with lysosomes. Cells 
can internalize surrounding substances by a phenomenon called pinocytosis/fluid phase endocytosis (II). Transcytosis is the main route 
for crossing of macromolecules through cells (III). Lipid rafts play a key role in signal transduction and macromolecules (e.g., cholera 
toxin, glycophosphatidylinositol (GPI)-anchored proteins and SV40 viral particles) internalization (IV). Endocytosis can occur through 
membranous caveolae and clathrin coated pits (V). The clathrin mediated endocytosis can be categorized as coated pits endocytosis 
(transferrin (Tf), low-density lipoprotein (LDL), some toxins, free fatty acids and viruses) and cholesterol-dependent clathrin-mediated 
endocytosis (e.g., toxins such as tetanus and anthrax toxins, PRPC, IL-2 receptor and APP). Once internalized, depending on the type 
vesicle, it can interact with other cellular compartments or vesicles such as endosomes and lysosomes and exocytose (VI) or even 
interact with the neighboring cells (VII). In the case of newly synthesized proteins, the secretory proteins such as glycoproteins are 
basically traversed across the membranes of endoplasmic reticulum (ER) and cis-face of Golgi apparatus through coat proteins (COP) I/
II. The matured peptides/proteins traverse through the cisternae and transporter out of the cells through vesicular trafficking from trans-
face of Golgi apparatus (red box). During such biosynthesis, maturation and post translational modification processes in the ER and 
Golgi apparatus, the sorting machineries get involved by recruiting a number of adaptor, retrieval and coat proteins such as and soluble 
N-ethylmaleimide sensitive attachment protein receptor (SNARE). These bio-elements are implemented for the fusion of vesicles (see 
Fig. 9) and various Rab  GTPases. For detailed information on vesicular trafficking readers are referred to the following citation.134,164,165  
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path,185,186 and the high binding capacity of cholesterol 
to caveolin-1, caveolae vesicles appear to be the main 
mediator of the cholesterol transportation. 
It seems to elicit similar effect(s) on the biogenesis 
formation of the clathrin-coated endocytic vesicles and 
synaptic vesicles. It should be noted that the caveolin-1 is 
capable of forming extremely robust detergent-resistant 
homo-oligomeric complexes (comprised of ~14 to 16 
monomers) that can further create higher oligomer-
oligomer complexes through interactions with the 
respective C-terminal domains – a process in favor of 
bending of the plasma membrane similar to that of the 
triskelion in the CCPs.182 Depending on the cell/tissue, the 
caveolae show different morphology such as grape-like 
clusters (abundant in developing skeletal muscle cells), 
rosettes (adipocytes), and detached vesicles/tubules in 
endothelial cells, as well as fused form as elongated tubules 
or transcellular channels.182 Caveolae-mediated vesicles 
are involved in endocytosis, transcytosis and potocytosis. 
While for the endocytosis, caveolae bud off from the 
plasma membrane and fuse with various intracellular 
compartments such as caveosomes interaction with ER, 
during the transcytosis, caveolae vesicles deliver proteins 
from one side to the other side of endothelial cells. As for 
the potocytosis (cellular drinking), caveolae vesicles are 
involved in the uptake of small solutes (<1 kDa) such as 
folate, in which the vesicles are pinched off and remained 
associated with the cell membrane, then undergo the 
caveolar fission/fusion through the SNARE complex and 
GTP hydrolysis (Figs. 8 and 9). 
While some recently conducted investigations implicated 
that caveolae and caveolin-mediated vesicles plays 
a check-and-balance role in the cerebral ischemia 
pathophysiology through incorporation with cholesterol 
molecules,187 it can be molecular target for treatment 
of these diseases. Further, the upregulation of caveolin 
in various malignancies make it an important cancer 
marker,188 while the endocytic capacity of the caveolar 
vesicles make this vesicular transportation route as an 
attractive mechanism for the targeted therapy, nonetheless 
caveolin-1 has been reported to be downregulated in some 
tumors. This vesicular mechanism has been shown to be 
beneficial path for macromolecular trafficking as reported 
for the endocytosis of atorvastatin calcium loaded BSA 
(ATV-BSA) nanoparticles (NPs), polyethylenimine (PEI), 
polyamidoamine (PAMAM) polyplexes and silica-coated 
iron oxide NPs.189-191
 
Clathrin-mediated endocytosis
Clathrin-mediated endocytosis (CME) is considered as 
the main RMTs process. During this vesicular trafficking 
phenomenon, CCPs/CCVs containing cargo molecules 
bud off from the plasma membrane and enter into the 
cytoplasm. Fig. 10 shows schematic illustration and 
transmission electron microscopy micrograph of the CCV. 
CME, as the most widely investigated vesicular 
transportation system, is a key step not only for the 
uptakes of nutrients and substances, but also for the 
intracellular signaling and membranous recycling. It 
should be noted that the binding of the receptors to the 
ligand molecules and activation of the receptors demand 
binding of intracellular part of the receptors to the adaptor 
proteins (Fig. 10A).192 Adaptor proteins play central roles 
in the assembly of the clathrin protein onto the plasma 
membrane.192 Of these, AP2 (subunits, α, β2, σ2, and μ2,) 
is one of the well-studied adapter proteins, which has a 
Fig. 9. Vesicular fusion through the SNARE complex and GTP hydrolysis.
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number of binding partners such as phosphatidylinositol 
4,5-bisphosphate (PIP2), clathrin, different endocytic 
accessory proteins, and two signaling motifs present on 
some cargo receptors (Fig. 10). The G-protein-coupled 
receptors (GPCRs) interact with various ligands (e.g., 
ions, amines, peptides, proteins, lipids, nucleotides, 
etc.), at which the receptor is activated with certain 
conformational changes towards plausible conversion of 
the receptor to the protein kinase substrate. The latter 
process results in binding of β-arrestins to the receptor, 
which is a necessary step for the internalization of cargo 
molecules through GPCR-mediated AP-2 adaptor protein 
complex and assisted by CME.192,193
Structurally, as shown in Fig. 10 (panel B), the clathrin-
mediated vesicles is characterized by three distinct 
layers as (i) the inner layer in which cargo molecules 
are interacted with their cognate receptor in association 
with adaptor protein, (ii) the internal layer consisting of 
lipid bilayer interacted with integrated proteins, and (iii) 
the outer layer containing triskelion assembled as the 
pentagons and hexagons. 
In general, the CME begins with (a) the interaction of cargo 
molecules with their cognate receptors, (b) the formation 
of vesicles on the inner surface of the cytoplasmic that 
possesses clathrin elements, (c) involvement of the AP2 
adaptor protein complex and accessory proteins. 
It should be highlighted that the subunits of AP2 adaptor 
complex initiate the formation of the clathrin matrix, 
in which some helper proteins (e.g., β-arrestins) are 
also involved. Once the α-subunit of AP2 attached to 
phosphatidylinositol-4,5-bisphosphate, it binds to the 
designated endocytic motifs through phosphorylation 
of μ2-subunit that results in binding of the μ2-subunit 
to the cargo protein undergoing endocytosis. All these 
events materialize the formation of CCVs, after which 
other accessory proteins such as clathrin assembly 
lymphoid myeloid leukemia (CALM) are literally 
involved to amalgamate the formation of clathrin lattice.194 
Concurrent with the emergence of clathrin matrix, various 
other proteins (dynamin and the actin cytoskeleton, 
rab5 guanine nucleotide exchange factor, Rme-6) are 
engaged to control the CCVs budding off, trafficking and 
recycling.195,196 
CME participates in vesicular trafficking of blood-
borne macromolecular substances into the brain by 
specialized functions at the BBB. Accordingly, the 
functional macromolecular trafficking through CCVs 
is important phenomenon not only for the maintenance 
of CNS homeostasis, but also for the targeted therapy of 
brain diseases such as brain tumors. For example, OX26 
mAb has been recruited for crossing the BBB, which is 
a RME mechanism implementing TfR-mediated CCVs. 
Accordingly, various OX26 functionalized NPs have been 
developed including solid lipid NPs, PEGylated liposomes 
and polymers such as chitosan and poly(lactic-co-glycolic 
acid).197-204 
Transcytosis 
As a well-known transport process, transcytosis was first 
introduced in capillary permeability studies. In addition 
to the paracellular entry of the macromolecules through 
normal or anomalous opening of the biological barriers 
(Fig. 2), transcytosis is the main route for the entrance 
of macromolecules into the tissue/organ from the 
surrounding biological barrier. As shown in Figs. 2 and 
8, transcytosis is an important process through which the 
cargo molecules move from one side of the cells to the 
other side bidirectionally (i.e., A-to-B and B-to-A). 
In the brain microvasculature endothelia, at least three 
mechanisms are involved in entry of the particulate 
substances into the brain, including:
(i) caveolae, in which the pits (50–100 nm and flask 
shape) formed plasma membrane (Fig. 8) enriched 
with cholesterol and sphingolipids similar to that 
of the lipid raft components, then get coated with 
flexible caveolin-1/2 and bud off from the membrane 
by the aid of GTPase dynamin to carry cargo 
molecules (e.g., folate receptor, tetanus toxins and 
Fig. 10. Clathrin coated pits and clathrin-mediated endocytosis. 
(A) Schematic representation of plasma membrane interaction 
with cargo receptor, adaptor proteins and clathrin. (B) Clathrin 
forms a non-covalently bound triskelton structure composed of 
three heavy chains (192 kDa each) and three light chains. (C) 
The transmission electron microscopy micrograph of clathrin-
coated pit in the brain capillary endothelial cell. (D) Schematic 
representation of assembled triskelion heavy and light chains 
forming pentagonic and hexagonic structure. (E) Triskelion heavy 
and light chains. Note: Not drown to scale.
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alkaline phosphatase),
(ii) clathrin, in which spherical pits (60–200 nm) bud 
off from plasma (Fig. 10) by the aid of AP2 forming 
semi-rigid matrix that is cleaved by the GTPase 
dynamin to transport cargo molecules (e.g., LDL, 
LRP1, transferrin, insulin); and
(iii) micropinocytosis, in which irregular spherical/
tubular vesicles (0.2-5 mM) perturb from 
the plasma membrane and are provoked by 
inflammation/lipopolysaccharide and shuffle various 
macromolecular entities.27 
At the BBB, up to 20 receptors have been recognized 
with ability to initiate receptor-mediated transcytosis, 
including: TfR, heparin-binding EGF, scavenger receptors 
AI, BI, EGF receptor, tumor necrosis factor, insulin and 
insulin-like growth factor receptors, apolipoprotein E 
receptor 2, leptin receptor, melanotransferrin receptor, 
LDL receptors. Most of these receptors are associated with 
CCVs to initiate transcytosis.27 Therefore, CCVs have 
been the main route for targeted delivery of nanoparticles 
and nanoconjugates into the brain.197,201,205-209 
Multifunctional nanomedicines for brain targeting 
While the currently used treatment modalities for brain 
diseases target the symptoms solely as noncurative 
agents, the nanoscaled DDSs show promising clinical 
outcomes by facilitating the drug delivery into the 
brain and improving the pharmacokinetics profile. 
However, these strategies need further investigations 
prior to their translation into clinical applications in 
human subjects. In fact, we need to improve our trifling 
understanding upon possible inadvertent neurotoxicity 
and detrimental effects of nanosized DDSs on neuronal 
cells. Targeting the cells within the central dogma 
brain is quit important for several formidable diseases 
such as neurodegenerative diseases and brain tumor 
gliomas. The latter disease has been classified into three 
major classes of astrocytomas, oligodendrogliomas 
and mixed gliomas (oligoastrocytomas), which cause a 
great deal of mortalities worldwide. Indeed, the targeted 
nanomedicines (e.g., polymeric/lipidic biodegradable 
NSs and inorganic nanoconjugates armed with targeting 
devices such as Tf or folic acid), with capability to cross 
BBB through active targeting mechanisms, can offer great 
benefits to patients with brain tumor.210 In 2014, Su et al. 
capitalized on a dual-targeting DDS drug delivery system 
using bovine serum albumin nanoparticles (BSA-NPs) 
modified with both lactoferrin (Lf) and mPEG2000. The 
engineered NPs were loaded with DOX molecules and 
examined in both in vitro and in vivo models. While the 
in vivo pharmacokinetics analysis in healthy rats showed 
longer circulation in rat, the PEGylated Lf-armed DOX-
loaded NPs induced profound toxicity in BCECs and C6 
cells. As a result, the engineered NS was proposed as an 
effective targeting therapy against brain gliomas.211 
Given that Baicalin poses remarkable neuroprotective 
impacts on ischemic tissues in neurodegeneration, Liu 
et at. (2015) engineered PEGylated cationic solid lipid 
NPs loaded with Baicalin and decorated with OX26 Ab 
(OX26-PEG-CSLN) with high encapsulation capacity 
(>80%) at a size range of about 30-50 nm.198 Based on 
the pharmacokinetics studies, they showed significantly 
higher AUC value of OX26-PEG-CSLN (11.08-fold 
higher) than that of the Baicalin solution alone, concluding 
OX26-PEG-CSLN as a promising NS for targeting brain 
disease.198
In a study, brain-targeted peptide angiopep-2 (ANG) 
was used for surface decoration of poly(lactic-co-glycolic 
acid) (PLGA) NPs encapsulating DOX and anti-EGFR 
siRNA. This multimodal NS was found to efficiently 
deliver DOX and siRNA into U87MG cells, causing 
marked cytotoxicity and apoptosis and suppressing EGFR. 
Once used in the animal, the analysis of brain orthotopic 
U87MG glioma xenograft mice revealed that the ANG-
armed PLGA NS was able to prolong the life span of the 
glioma-bearing mice.205 Clark and Davis decorated Gold 
NPs (AuNPs) with Tf through an acid-cleavable linkage 
or anti-TfR Ab. They showed high affinity and avidity of 
Tf-armed AuNPs to TfRs on the blood side of the BBB. 
Once internalized, the multidentate Tf-TfR interactions 
was easily dissociated in large part because of acidification 
during the vesicular trafficking. Such mechanism was 
shown to profoundly enhance the entrance of NPs into 
the brain parenchyma of mice. While these researchers 
confirmed the trafficking of high-affinity anti-TfR Abs 
through lysosomal compartments of BCECs, they showed 
that the high-avidity Tf-armed AuNPs with the acid-
cleavable linkage was able to avoid the major endothelium 
retention in large part through shedding surface Tf during 
their transcytosis.212
Recently, an “autocatalytic” approach was projected to 
enhance the transportation of NPs into the brain based 
upon entrance of a small number of NPs and liberation of 
specific modulators with capability to mediate the entry of 
more NPs into the brain.213 The autocatalytic brain tumor-
targeting poly(amine-co-ester) terpolymer NPs was used 
with results showing their ability to preferentially highly 
accumulate in brain tumors though through a passive 
targeting mechanism. 
In 2014, Zong et al. developed a dual-targeting liposomal 
NS loaded with DOX and conjugated with cell-penetrating 
peptide (TAT) and Tf. Having examined in both in vitro 
and in vivo models, these researchers showed significantly 
high penetration of the dual-targeting NS across BCECs 
and marked accumulation in tumor cells. Based upon 
their findings by in vivo imaging, the engineered NS was 
able to reach the core of the tumor spheroids, resulting in 
marked increase in survival time of tumor-bearing mice 
after treatment in comparison with free drug molecules.214
Another study was later on conducted to investigate the 
effectiveness of similar NS in targeted delivery of anti-
EGFR siRNA to tumor bearing mice.215 And, substantially 
long survival period and great downregulation in the 
expression of EGFR was reported in mice treated with such 
NS. As a result, it seems that the Tf-TAT conjugated NPs 
may be considered as a promising NS for shuttling drugs/
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genes into the brain. In fact, various biological capacities 
of BBB such as CMTs and RMTs can be exploited for 
the specific targeting of brain diseases using different 
strategies.216 
Concluding remakes
The BBB selectively/specifically controls/regulates 
the traverse of blood-circulating substances into the 
brain and vice versa, by which the CNS homeostasis is 
conservatively maintained. Such biological barrier also 
selectively controls the entrance of medicines necessary 
for diagnosis and/or therapy of the CNS diseases. The 
CMT and RMT machineries of the BBB can clinically be 
of great importance not only in terms of pathobiology 
of brain capillary endothelial cells and surrounding 
parenchymal cells, but also for drug discovery, delivery 
and targeting. In fact, our current challenge in CNS dreg 
delivery dilemma is how to exploit the naturally occurring 
vesicular trafficking systems and the receptor-mediated 
transfer machinery in safely crossing the BBB. We may 
also consider focusing our endeavors on exploiting 
multifunctional nanoscaled drug delivery systems (DDSs) 
to efficiently cross the restricted barrier and safely carry out 
the designated diagnostic or deliver therapeutic medicines 
to the target site(s) within the brain without imposing 
undesired impacts.217 There have been a large number 
of investigations on developing smart multimodal brain 
drug delivery and targeting systems. While discussion on 
this subject was beyond the objective of this review, to the 
best of our knowledge, such DDSs are yet to be developed. 
Although multifunctional nanomedicines are supposed 
to be able to enter the brain exploiting the endocytic 
machineries mainly through functionalized ligands, their 
safety and nonspecific impacts on the brain parenchymal 
entities yet to be fully evaluated. 
Acknowledgments 
Authors like to acknowledge Tabriz University of Medical Sciences for 
the financial support of the brain drug delivery and targeting project. 
Ethical approval 
There is none to be disclosed. 
Competing interests 
The authors like to declare that JB, MR and YO are the current editors of 
the journal. The publication process (blind peer-review) of the current 
article has been performed in accordance with the COPE guidelines. 
References
1. Omidi Y, Barar J. Impacts of blood-brain barrier in drug delivery 
and targeting of brain tumors. Bioimpacts 2012; 2: 5-22. doi: 
10.5681/bi.2012.002
2. Willis CL. Imaging in vivo astrocyte/endothelial cell interactions at 
the blood-brain barrier. Methods Mol Biol 2012; 814: 515-29. doi: 
10.1007/978-1-61779-452-0_34
3. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial 
interactions at the blood-brain barrier. Nat Rev Neurosci 2006; 7: 
41-53. doi: 10.1038/nrn1824
4. Omidi Y, Barar J, Ahmadian S, Heidari HR, Gumbleton M. 
Characterization and astrocytic modulation of system L 
transporters in brain microvasculature endothelial cells. Cell 
What is current knowledge?
√ Brain capillary endothelial cells (BCECs) form blood-brain 
barrier (BBB).
√ BBB selectively/specifically controls the inward and/or 
outward traverse of nutrients/substances through carrier- 
and/or receptor-mediated transport machineries of BCECs. 
What is new here?
√ Carrier- and/or receptor-mediated transport machineries 
of BCECs can be exploited for rationalized drug discovery 
and development.
√ For targeted therapy of brain diseases, the capacity of 
carrier- and/or receptor-mediated transport machineries of 
BCECs can be exploited.
Review Highlights
Biochem Funct 2008; 26: 381-91. doi: 10.1002/cbf.1455
5. Pardridge WM. Molecular biology of the blood-brain barrier. Mol 
Biotechnol 2005; 30: 57-70. doi: 10.1385/MB:30:1:057
6. Miller DS. Regulation of ABC transporters at the blood-brain 
barrier. Clin Pharmacol Ther 2015; 97: 395-403. doi: 10.1002/cpt.64
7. Begley DJ. ABC transporters and the blood-brain barrier. Curr 
Pharm Des 2004; 10: 1295-312. 
8. Pardridge WM. Drug transport across the blood-brain barrier. 
J Cereb Blood Flow Metab 2012; 32: 1959-72. doi: 10.1038/
jcbfm.2012.126
9. Pardridge WM. Drug targeting to the brain. Pharm Res 2007; 24: 
1733-44. doi: 10.1007/s11095-007-9324-2
10. Wood MJ, O’Loughlin AJ, Samira L. Exosomes and the blood-brain 
barrier: implications for neurological diseases. Ther Deliv 2011; 2: 
1095-9. 
11. Rafi MA, Omidi Y. A prospective highlight on exosomal 
nanoshuttles and cancer immunotherapy and vaccination. 
Bioimpacts 2015; 5: 117-22. doi: 10.15171/bi.2015.22
12. O’Loughlin AJ, Woffindale CA, Wood MJ. Exosomes and the 
emerging field of exosome-based gene therapy. Curr Gene Ther 
2012; 12: 262-74. 
13. Grapp M, Wrede A, Schweizer M, Huwel S, Galla HJ, Snaidero N, et 
al. Choroid plexus transcytosis and exosome shuttling deliver folate 
into brain parenchyma. Nat Commun 2013; 4: 2123. doi: 10.1038/
ncomms3123
14. Sun D, Zhuang X, Zhang S, Deng ZB, Grizzle W, Miller D, et al. 
Exosomes are endogenous nanoparticles that can deliver biological 
information between cells. Adv Drug Deliv Rev 2013; 65: 342-7. doi: 
10.1016/j.addr.2012.07.002
15. Gumbleton M, Audus KL. Progress and limitations in the use of in 
vitro cell cultures to serve as a permeability screen for the blood-
brain barrier. J Pharm Sci 2001; 90: 1681-98. 
16. Smith M, Omidi Y, Gumbleton M. Primary porcine brain 
microvascular endothelial cells: biochemical and functional 
characterisation as a model for drug transport and targeting. J Drug 
Target 2007; 15: 253-68. doi: 10.1080/10611860701288539
17. Barar J, Gumbleton M, Asadi M, Omidi Y. Barrier functionality 
and transport machineries of human ECV304 cells. Med Sci Monit 
2010; 16: BR52-60. 
18. Nakhlband A, Omidi Y. Barrier functionality of porcine and bovine 
brain capillary endothelial cells. Bioimpacts 2011; 1: 153-9. doi: 
10.5681/bi.2011.021
19. Omidi Y, Campbell L, Barar J, Connell D, Akhtar S, Gumbleton M. 
Evaluation of the immortalised mouse brain capillary endothelial 
cell line, b.End3, as an in vitro blood-brain barrier model for drug 
uptake and transport studies. Brain Res 2003; 990: 95-112. 
20. Katt ME, Xu ZS, Gerecht S, Searson PC. Human Brain 
BBB transporters and targeted therapy of brain diseases
BioImpacts, 2016, 6(4), 225-248 243
Microvascular Endothelial Cells Derived from the BC1 iPS Cell 
Line Exhibit a Blood-Brain Barrier Phenotype. PLoS One 2016; 11: 
e0152105. doi:10.1371/journal.pone.0152105 
21. Helms HC, Abbott NJ, Burek M, Cecchelli R, Couraud PO, Deli 
MA, et al. In vitro models of the blood-brain barrier: An overview 
of commonly used brain endothelial cell culture models and 
guidelines for their use. J Cereb Blood Flow Metab 2016; 36: 862-90. 
doi: 10.1177/0271678X16630991
22. Rapoport SI. Osmotic opening of the blood-brain barrier. Ciba 
Found Symp 1978; 237-55. 
23. Easton AS, Abbott NJ. Bradykinin increases permeability by 
calcium and 5-lipoxygenase in the ECV304/C6 cell culture model 
of the blood-brain barrier. Brain Res 2002; 953: 157-69. 
24. Sanovich E, Bartus RT, Friden PM, Dean RL, Le HQ, Brightman 
MW. Pathway across blood-brain barrier opened by the bradykinin 
agonist, RMP-7. Brain Res 1995; 705: 125-35
25. Abbott NJ. Inflammatory mediators and modulation of blood-
brain barrier permeability. Cell Mol Neurobiol 2000; 20: 131-47. 
26. Pardridge WM. Blood-brain barrier endogenous transporters 
as therapeutic targets: a new model for small molecule CNS 
drug discovery. Expert Opin Ther Targets 2015; 19: 1059-72. doi: 
10.1517/14728222.2015.1042364
27. Preston JE, Joan Abbott N, Begley DJ. Transcytosis of 
macromolecules at the blood-brain barrier. Adv Pharmacol 2014; 
71: 147-63. doi: 10.1016/bs.apha.2014.06.001
28. Wang YY, Lui PC, Li JY. Receptor-mediated therapeutic transport 
across the blood-brain barrier. Immunotherapy 2009; 1: 983-93. 
doi: 10.2217/imt.09.75
29. de Boer AG, Gaillard PJ. Drug targeting to the brain. Annu Rev 
Pharmacol Toxicol 2007; 47: 323-55. doi: 10.1146/annurev.
pharmtox.47.120505.105237
30. Peluffo H, Unzueta U, Negro-Demontel ML, Xu Z, Vaquez E, Ferrer-
Miralles N, et al. BBB-targeting, protein-based nanomedicines for 
drug and nucleic acid delivery to the CNS. Biotechnol Adv 2015; 33: 
277-87. doi: 10.1016/j.biotechadv.2015.02.004
31. Patil R, Ljubimov AV, Gangalum PR, Ding H, Portilla-Arias J, 
Wagner S, et al. MRI virtual biopsy and treatment of brain metastatic 
tumors with targeted nanobioconjugates: nanoclinic in the brain. 
ACS Nano 2015; 9: 5594-608. doi: 10.1021/acsnano.5b01872
32. Gao H, Yang Z, Zhang S, Pang Z, Liu Q, Jiang X. Study and evaluation 
of mechanisms of dual targeting drug delivery system with tumor 
microenvironment assays compared with normal assays. Acta 
Biomater 2014; 10: 858-67. doi: 10.1016/j.actbio.2013.11.003
33. Gao H, Yang Z, Zhang S, Pang Z, Jiang X. Internalization 
and subcellular fate of aptamer and peptide dual-
functioned nanoparticles. J Drug Target 2014; 22: 450-9. doi: 
10.3109/1061186X.2014.886038
34. Ma H, Gao Z, Yu P, Shen S, Liu Y, Xu B. A dual functional 
fluorescent probe for glioma imaging mediated by blood-brain 
barrier penetration and glioma cell targeting. Biochem Biophys Res 
Commun 2014; 449: 44-8. doi: 10.1016/j.bbrc.2014.04.148
35. Ordovas JM. ABC1: the gene for Tangier disease and beyond. Nutr 
Rev 2000; 58: 76-9. 
36. Chen P, Dai Y, Wu X, Wang Y, Sun S, Xiao J, et al. Mutations in the 
ABCA3 gene are associated with cataract-microcornea syndrome. 
Invest Ophthalmol Vis Sci 2014; 55: 8031-43. doi: 10.1167/iovs.14-
14098
37. Maeda A, Maeda T, Golczak M, Palczewski K. Retinopathy in mice 
induced by disrupted all-trans-retinal clearance. J Biol Chem 2008; 
283: 26684-93. doi: 10.1074/jbc.M804505200
38. Steinberg S, Stefansson H, Jonsson T, Johannsdottir H, Ingason A, 
Helgason H, et al. Loss-of-function variants in ABCA7 confer risk 
of Alzheimer’s disease. Nat Genet 2015; 47: 445-7. doi: 10.1038/
ng.3246
39. DeStefano GM, Kurban M, Anyane-Yeboa K, Dall’Armi C, Di 
Paolo G, Feenstra H, et al. Mutations in the cholesterol transporter 
gene ABCA5 are associated with excessive hair overgrowth. PLoS 
Genet 2014; 10: e1004333. doi: 10.1371/journal.pgen.1004333
40. Kelsell DP, Norgett EE, Unsworth H, Teh MT, Cullup T, Mein CA, 
et al. Mutations in ABCA12 underlie the severe congenital skin 
disease harlequin ichthyosis. Am J Hum Genet 2005; 76: 794-803. 
doi: 10.1086/429844
41. Girodon-Boulandet E, Cazeneuve C, Goossens M. Screening 
practices for mutations in the CFTR gene ABCC7. Hum Mutat 2000; 
15: 135-49. doi: 10.1002/(SICI)1098-1004(200002)15:2<135::AID-
HUMU2>3.0.CO;2-H
42. Hoffmann K, Gastens AM, Volk HA, Loscher W. Expression of 
the multidrug transporter MRP2 in the blood-brain barrier after 
pilocarpine-induced seizures in rats. Epilepsy Res 2006; 69: 1-14. 
doi: 10.1016/j.eplepsyres.2005.12.005
43. Ose A, Ito M, Kusuhara H, Yamatsugu K, Kanai M, Shibasaki M, et 
al. Limited brain distribution of [3R,4R,5S]-4-acetamido-5-amino-
3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 
64-0802), a pharmacologically active form of oseltamivir, by active 
efflux across the blood-brain barrier mediated by organic anion 
transporter 3 (Oat3/Slc22a8) and multidrug resistance-associated 
protein 4 (Mrp4/Abcc4). Drug Metab Dispos 2009; 37: 315-21. doi: 
10.1124/dmd.108.024018
44. Musolino PL, Gong Y, Snyder JM, Jimenez S, Lok J, Lo EH, et al. 
Brain endothelial dysfunction in cerebral adrenoleukodystrophy. 
Brain 2015; 138: 3206-20. doi: 10.1093/brain/awv250
45. Huang B, Zhou H, Lang X, Liu Z. siRNAinduced ABCE1 silencing 
inhibits proliferation and invasion of breast cancer cells. Mol Med 
Rep 2014; 10: 1685-90. doi: 10.3892/mmr.2014.2424
46. Liu YH, Chen YJ, Wu HH, Wang TY, Tsai FJ. Single nucleotide 
polymorphisms at the PRR3, ABCF1, and GNL1 genes in the HLA 
class I region are associated with Graves’ ophthalmopathy in a 
gender-dependent manner. Ophthalmology 2014; 121: 2033-9. doi: 
10.1016/j.ophtha.2014.04.027
47. Powell TR, Tansey KE, Breen G, Farmer AE, Craig IW, Uher R, 
et al. ATP-binding cassette sub-family F member 1 (ABCF1) is 
identified as a putative therapeutic target of escitalopram in the 
inflammatory cytokine pathway. J Psychopharmacol 2013; 27: 609-
15. doi: 10.1177/0269881113490329
48. Bojanic DD, Tarr PT, Gale GD, Smith DJ, Bok D, Chen B, et al. 
Differential expression and function of ABCG1 and ABCG4 
during development and aging. J Lipid Res 2010; 51: 169-81. doi: 
10.1194/M900250-JLR200
49. Nicolazzo JA, Katneni K. Drug transport across the blood-brain 
barrier and the impact of breast cancer resistance protein (ABCG2). 
Curr Top Med Chem 2009; 9: 130-47. 
50. Mantych GJ, James DE, Devaskar SU. Jejunal/kidney glucose 
transporter isoform (Glut-5) is expressed in the human blood-
brain barrier. Endocrinology 1993; 132: 35-40. doi: 10.1210/
endo.132.1.8419132
51. Pardridge WM, Boado RJ, Farrell CR. Brain-type glucose 
transporter (GLUT-1) is selectively localized to the blood-brain 
barrier. Studies with quantitative western blotting and in situ 
hybridization. J Biol Chem 1990; 265: 18035-40. 
52. Halestrap AP. Monocarboxylic acid transport. Compr Physiol 2013; 
3: 1611-43. doi: 10.1002/cphy.c130008
53. Miller LP, Oldendorf WH. Regional kinetic constants for blood-
brain barrier pyruvic acid transport in conscious rats by the 
monocarboxylic acid carrier. J Neurochem 1986; 46: 1412-6. 
54. Oldendorf WH. Carrier-mediated blood-brain barrier transport 
of short-chain monocarboxylic organic acids. Am J Physiol 1973; 
224: 1450-3. 
55. Conn AR, Fell DI, Steele RD. Characterization of alpha-keto acid 
transport across blood-brain barrier in rats. Am J Physiol 1983; 
245: E253-60. 
56. Ceballos A, Belinchon MM, Sanchez-Mendoza E, Grijota-
Martinez C, Dumitrescu AM, Refetoff S, et al. Importance of 
monocarboxylate transporter 8 for the blood-brain barrier-
dependent availability of 3,5,3’-triiodo-L-thyronine. Endocrinology 
2009; 150: 2491-6. doi: 10.1210/en.2008-1616
57. Kido Y, Tamai I, Uchino H, Suzuki F, Sai Y, Tsuji A. Molecular and 
functional identification of large neutral amino acid transporters 
LAT1 and LAT2 and their pharmacological relevance at the blood-
Omidi et al
BioImpacts, 2016, 6(4), 225-248244
brain barrier. J Pharm Pharmacol 2001; 53: 497-503. 
58. Kageyama T, Nakamura M, Matsuo A, Yamasaki Y, Takakura Y, 
Hashida M, et al. The 4F2hc/LAT1 complex transports L-DOPA 
across the blood-brain barrier. Brain Res 2000; 879: 115-21. 
59. Rautio J, Gynther M, Laine K. LAT1-mediated prodrug uptake: a 
way to breach the blood-brain barrier? Ther Deliv 2013; 4: 281-4. 
doi: 10.4155/tde.12.165
60. Sakaeda T, Siahaan TJ, Audus KL, Stella VJ. Enhancement of 
transport of D-melphalan analogue by conjugation with L-glutamate 
across bovine brain microvessel endothelial cell monolayers. J Drug 
Target 2000; 8: 195-204. doi: 10.3109/10611860008996865
61. O’Kane RL, Martinez-Lopez I, DeJoseph MR, Vina JR, Hawkins 
RA. Na(+)-dependent glutamate transporters (EAAT1, EAAT2, 
and EAAT3) of the blood-brain barrier. A mechanism for glutamate 
removal. J Biol Chem 1999; 274: 31891-5. 
62. Benrabh H, Lefauconnier JM. Glutamate is transported across the 
rat blood-brain barrier by a sodium-independent system. Neurosci 
Lett 1996; 210: 9-12. 
63. O’Kane RL, Vina JR, Simpson I, Zaragoza R, Mokashi A, Hawkins 
RA. Cationic amino acid transport across the blood-brain barrier is 
mediated exclusively by system y+. Am J Physiol Endocrinol Metab 
2006; 291: E412-9. doi: 10.1152/ajpendo.00007.2006
64. Stoll J, Wadhwani KC, Smith QR. Identification of the cationic 
amino acid transporter (System y+) of the rat blood-brain barrier. 
J Neurochem 1993; 60: 1956-9. 
65. Benrabh H, Bourre JM, Lefauconnier JM. Taurine transport at the 
blood-brain barrier: an in vivo brain perfusion study. Brain Res 
1995; 692: 57-65. 
66. Tamai I, Senmaru M, Terasaki T, Tsuji A. Na(+)- and Cl(-)-
dependent transport of taurine at the blood-brain barrier. Biochem 
Pharmacol 1995; 50: 1783-93. 
67. Komura J, Tamai I, Senmaru M, Terasaki T, Sai Y, Tsuji A. Brain-
to-blood active transport of beta-alanine across the blood-brain 
barrier. FEBS Lett 1997; 400: 131-5. 
68. Murakami H, Sawada N, Koyabu N, Ohtani H, Sawada Y. 
Characteristics of choline transport across the blood-brain barrier 
in mice: correlation with in vitro data. Pharm Res 2000; 17: 1526-
30. 
69. Kang YS, Terasaki T, Ohnishi T, Tsuji A. In vivo and in vitro 
evidence for a common carrier mediated transport of choline and 
basic drugs through the blood-brain barrier. J Pharmacobiodyn 
1990; 13: 353-60. 
70. Karlsson C, Maepea O, Alm A. Choline transport through the 
blood-retinal and the blood-brain barrier in vivo. Acta Ophthalmol 
(Copenh) 1984; 62: 763-6. 
71. Masereeuw R, Jaehde U, Langemeijer MW, de Boer AG, Breimer 
DD. In vitro and in vivo transport of zidovudine (AZT) across the 
blood-brain barrier and the effect of transport inhibitors. Pharm 
Res 1994; 11: 324-30. 
72. Tsuji A, Tamai I. Organic anion transporters. Pharm Biotechnol 
1999; 12: 471-91. 
73. Tsuji A, Tamai II. Carrier-mediated or specialized transport of 
drugs across the blood-brain barrier. Adv Drug Deliv Rev 1999; 36: 
277-90. 
74. Adkison KD, Shen DD. Uptake of valproic acid into rat brain is 
mediated by a medium-chain fatty acid transporter. J Pharmacol 
Exp Ther 1996; 276: 1189-200. 
75. Dick AP, Harik SI, Klip A, Walker DM. Identification and 
characterization of the glucose transporter of the blood-brain 
barrier by cytochalasin B binding and immunological reactivity. 
Proc Natl Acad Sci U S A 1984; 81: 7233-7. 
76. Morgello S, Uson RR, Schwartz EJ, Haber RS. The human blood-
brain barrier glucose transporter (GLUT1) is a glucose transporter 
of gray matter astrocytes. Glia 1995; 14: 43-54. doi: 10.1002/
glia.440140107
77. Cornford EM, Nguyen EV, Landaw EM. Acute upregulation of 
blood-brain barrier glucose transporter activity in seizures. Am J 
Physiol Heart Circ Physiol 2000; 279: H1346-54. 
78. Shah K, Desilva S, Abbruscato T. The role of glucose transporters 
in brain disease: diabetes and Alzheimer’s Disease. Int J Mol Sci 
2012; 13: 12629-55. doi: 10.3390/ijms131012629
79. Winkler EA, Nishida Y, Sagare AP, Rege SV, Bell RD, Perlmutter D, 
et al. GLUT1 reductions exacerbate Alzheimer’s disease vasculo-
neuronal dysfunction and degeneration. Nat Neurosci 2015; 18: 
521-30. doi: 10.1038/nn.3966
80. Seidner G, Alvarez MG, Yeh JI, O’Driscoll KR, Klepper J, Stump TS, 
et al. GLUT-1 deficiency syndrome caused by haploinsufficiency of 
the blood-brain barrier hexose carrier. Nat Genet 1998; 18: 188-91. 
doi:10.1038/ng0298-188
81. Humphrey W, Dalke A, Schulten K. VMD: visual molecular 
dynamics. J Mol Graph 1996; 14: 33-8, 27-8. 
82. Halestrap AP, Wilson MC. The monocarboxylate transporter 
family--role and regulation. IUBMB Life 2012; 64: 109-19. doi: 
10.1002/iub.572
83. Ullah MS, Davies AJ, Halestrap AP. The plasma membrane lactate 
transporter MCT4, but not MCT1, is up-regulated by hypoxia 
through a HIF-1alpha-dependent mechanism. J Biol Chem 2006; 
281: 9030-7. doi: 10.1074/jbc.M511397200
84. Perez de Heredia F, Wood IS, Trayhurn P. Hypoxia stimulates 
lactate release and modulates monocarboxylate transporter 
(MCT1, MCT2, and MCT4) expression in human adipocytes. 
Pflugers Arch 2010; 459: 509-18. doi: 10.1007/s00424-009-0750-3
85. Kinne A, Schulein R, Krause G. Primary and secondary thyroid 
hormone transporters. Thyroid Res 2011; 4 Suppl 1: S7. doi: 
10.1186/1756-6614-4-S1-S7
86. Van Herck SL, Delbaere J, Bourgeois NM, McAllan BM, Richardson 
SJ, Darras VM. Expression of thyroid hormone transporters 
and deiodinases at the brain barriers in the embryonic chicken: 
Insights into the regulation of thyroid hormone availability during 
neurodevelopment. Gen Comp Endocrinol 2015; 214: 30-9. doi: 
10.1016/j.ygcen.2015.02.021
87. Grillon E, Farion R, Fablet K, De Waard M, Tse CM, Donowitz M, 
et al. The spatial organization of proton and lactate transport in a 
rat brain tumor. PLoS One 2011; 6: e17416. doi: 10.1371/journal.
pone.0017416
88. Miranda-Goncalves V, Granja S, Martinho O, Honavar M, Pojo 
M, Costa BM, et al. Hypoxia-mediated upregulation of MCT1 
expression supports the glycolytic phenotype of glioblastomas. 
Oncotarget 2016. doi: 10.18632/oncotarget.10114
89. Barar J, Omidi Y. Dysregulated pH in Tumor Microenvironment 
Checkmates Cancer Therapy. Bioimpacts 2013; 3: 149-62. doi: 
10.5681/bi.2013.036
90. Omidi Y, Barar J. Targeting tumor microenvironment: crossing 
tumor interstitial fluid by multifunctional nanomedicines. 
Bioimpacts 2014; 4: 55-67. doi: 10.5681/bi.2014.021
91. Verrey F, Meier C, Rossier G, Kuhn LC. Glycoprotein-associated 
amino acid exchangers: broadening the range of transport 
specificity. Pflugers Arch 2000; 440: 503-12. 
92. Wagner CA, Broer A, Albers A, Gamper N, Lang F, Broer S. The 
heterodimeric amino acid transporter 4F2hc/LAT1 is associated 
in Xenopus oocytes with a non-selective cation channel that is 
regulated by the serine/threonine kinase sgk-1. J Physiol 2000; 526 
Pt 1: 35-46. 
93. Broer A, Friedrich B, Wagner CA, Fillon S, Ganapathy V, Lang F, et 
al. Association of 4F2hc with light chains LAT1, LAT2 or y+LAT2 
requires different domains. Biochem J 2001; 355: 725-31. 
94. Wagner CA, Lang F, Broer S. Function and structure of 
heterodimeric amino acid transporters. Am J Physiol Cell Physiol 
2001; 281: C1077-93. 
95. Hosoya K, Tomi M, Ohtsuki S, Takanaga H, Saeki S, Kanai Y, et 
al. Enhancement of L-cystine transport activity and its relation to 
xCT gene induction at the blood-brain barrier by diethyl maleate 
treatment. J Pharmacol Exp Ther 2002; 302: 225-31. 
96. Verrey F. System L: heteromeric exchangers of large, neutral amino 
acids involved in directional transport. Pflugers Arch 2003; 445: 
529-33. doi: 10.1007/s00424-002-0973-z
97. Seow HF, Broer S, Broer A, Bailey CG, Potter SJ, Cavanaugh JA, et 
al. Hartnup disorder is caused by mutations in the gene encoding 
BBB transporters and targeted therapy of brain diseases
BioImpacts, 2016, 6(4), 225-248 245
the neutral amino acid transporter SLC6A19. Nat Genet 2004; 36: 
1003-7. doi: 10.1038/ng1406
98. Broer S. The role of the neutral amino acid transporter B0AT1 
(SLC6A19) in Hartnup disorder and protein nutrition. IUBMB Life 
2009; 61: 591-9. doi: 10.1002/iub.210
99. Saadi I, Chen XZ, Hediger M, Ong P, Pereira P, Goodyer P, et al. 
Molecular genetics of cystinuria: mutation analysis of SLC3A1 and 
evidence for another gene in type I (silent) phenotype. Kidney Int 
1998; 54: 48-55. doi: 10.1046/j.1523-1755.1998.00956.x
100. Koulivand L, Mohammadi M, Ezatpour B, Salehi R, Markazi S, 
Dashti S, et al. Mutation analysis of SLC3A1 and SLC7A9 genes in 
patients with cystinuria. Urolithiasis 2015; 43: 447-53. doi: 10.1007/
s00240-015-0794-0
101. Markazi S, Kheirollahi M, Doosti A, Mohammadi M, Koulivand 
L. A Novel Mutation in SLC3A1 Gene in Patients With Cystinuria. 
Iran J Kidney Dis 2016; 10: 44-7. 
102. Matsuo H, Tsukada S, Nakata T, Chairoungdua A, Kim DK, Cha 
SH, et al. Expression of a system L neutral amino acid transporter 
at the blood-brain barrier. Neuroreport 2000; 11: 3507-11. 
103. Nii T, Segawa H, Taketani Y, Tani Y, Ohkido M, Kishida S, et 
al. Molecular events involved in up-regulating human Na+-
independent neutral amino acid transporter LAT1 during T-cell 
activation. Biochem J 2001; 358: 693-704. 
104. Kim DK, Kanai Y, Choi HW, Tangtrongsup S, Chairoungdua 
A, Babu E, et al. Characterization of the system L amino acid 
transporter in T24 human bladder carcinoma cells. Biochim 
Biophys Acta 2002; 1565: 112-21. 
105. Kanai Y, Endou H. Functional properties of multispecific amino 
acid transporters and their implications to transporter-mediated 
toxicity. J Toxicol Sci 2003; 28: 1-17. 
106. Boado RJ, Li JY, Nagaya M, Zhang C, Pardridge WM. Selective 
expression of the large neutral amino acid transporter at the blood-
brain barrier. Proc Natl Acad Sci U S A 1999; 96: 12079-84. 
107. Meier C, Ristic Z, Klauser S, Verrey F. Activation of system L 
heterodimeric amino acid exchangers by intracellular substrates. 
EMBO J 2002; 21: 580-9. 
108. Friesema EC, Docter R, Moerings EP, Verrey F, Krenning 
EP, Hennemann G, et al. Thyroid hormone transport by 
the heterodimeric human system L amino acid transporter. 
Endocrinology 2001; 142: 4339-48. doi: 10.1210/endo.142.10.8418
109. Yanagida O, Kanai Y, Chairoungdua A, Kim DK, Segawa H, 
Nii T, et al. Human L-type amino acid transporter 1 (LAT1): 
characterization of function and expression in tumor cell lines. 
Biochim Biophys Acta 2001; 1514: 291-302. 
110. Segawa H, Fukasawa Y, Miyamoto K, Takeda E, Endou H, Kanai 
Y. Identification and functional characterization of a Na+-
independent neutral amino acid transporter with broad substrate 
selectivity. J Biol Chem 1999; 274: 19745-51. 
111. Vumma R, Wiesel FA, Flyckt L, Bjerkenstedt L, Venizelos N. 
Functional characterization of tyrosine transport in fibroblast 
cells from healthy controls. Neurosci Lett 2008; 434: 56-60. doi: 
10.1016/j.neulet.2008.01.028
112. Rossier G, Meier C, Bauch C, Summa V, Sordat B, Verrey F, et 
al. LAT2, a new basolateral 4F2hc/CD98-associated amino acid 
transporter of kidney and intestine. J Biol Chem 1999; 274: 34948-
54. 
113. Dolgodilina E, Imobersteg S, Laczko E, Welt T, Verrey F, Makrides 
V. Brain interstitial fluid glutamine homeostasis is controlled by 
blood-brain barrier SLC7A5/LAT1 amino acid transporter. J Cereb 
Blood Flow Metab 2015. doi: 10.1177/0271678X15609331
114. Ylikangas H, Malmioja K, Peura L, Gynther M, Nwachukwu EO, 
Leppanen J, et al. Quantitative insight into the design of compounds 
recognized by the L-type amino acid transporter 1 (LAT1). 
ChemMedChem 2014; 9: 2699-707. doi: 10.1002/cmdc.201402281
115. Peura L, Malmioja K, Laine K, Leppanen J, Gynther M, Isotalo A, 
et al. Large amino acid transporter 1 (LAT1) prodrugs of valproic 
acid: new prodrug design ideas for central nervous system delivery. 
Mol Pharm 2011; 8: 1857-66. doi: 10.1021/mp2001878
116. del Amo EM, Urtti A, Yliperttula M. Pharmacokinetic role of 
L-type amino acid transporters LAT1 and LAT2. Eur J Pharm Sci 
2008; 35: 161-74. doi: 10.1016/j.ejps.2008.06.015
117. Fan X, Ross DD, Arakawa H, Ganapathy V, Tamai I, Nakanishi 
T. Impact of system L amino acid transporter 1 (LAT1) on 
proliferation of human ovarian cancer cells: a possible target for 
combination therapy with anti-proliferative aminopeptidase 
inhibitors. Biochem Pharmacol 2010; 80: 811-8. doi: 10.1016/j.
bcp.2010.05.021
118. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, 
et al. Prognostic significance of L-type amino acid transporter 1 
(LAT1) and 4F2 heavy chain (CD98) expression in surgically 
resectable stage III non-small cell lung cancer. Exp Ther Med 2010; 
1: 799-808. doi: 10.3892/etm.2010.117
119. Kaira K, Takahashi T, Murakami H, Shukuya T, Kenmotsu H, 
Naito T, et al. Relationship between LAT1 expression and response 
to platinum-based chemotherapy in non-small cell lung cancer 
patients with postoperative recurrence. Anticancer Res 2011; 31: 
3775-82. 
120. Kaira K, Arakawa K, Shimizu K, Oriuchi N, Nagamori S, Kanai Y, 
et al. Relationship between CD147 and expression of amino acid 
transporters (LAT1 and ASCT2) in patients with pancreatic cancer. 
Am J Transl Res 2015; 7: 356-63. 
121. Huttunen KM, Gynther M, Huttunen J, Puris E, Spicer JA, Denny 
WA. A Selective and Slowly Reversible Inhibitor of l-Type Amino 
Acid Transporter 1 (LAT1) Potentiates Antiproliferative Drug 
Efficacy in Cancer Cells. J Med Chem 2016; 59: 5740-51. doi: 
10.1021/acs.jmedchem.6b00190
122. Fukumoto S, Hanazono K, Fu DR, Endo Y, Kadosawa T, Iwano H, 
et al. A new treatment for human malignant melanoma targeting 
L-type amino acid transporter 1 (LAT1): a pilot study in a canine 
model. Biochem Biophys Res Commun 2013; 439: 103-8. doi: 
10.1016/j.bbrc.2013.08.020
123. Rosilio C, Nebout M, Imbert V, Griessinger E, Neffati Z, Benadiba 
J, et al. L-type amino-acid transporter 1 (LAT1): a therapeutic 
target supporting growth and survival of T-cell lymphoblastic 
lymphoma/T-cell acute lymphoblastic leukemia. Leukemia 2015; 
29: 1253-66. doi: 10.1038/leu.2014.338
124. Wu W, Dong Y, Gao J, Gong M, Zhang X, Kong W, et al. 
Aspartate-modified doxorubicin on its N-terminal increases drug 
accumulation in LAT1-overexpressing tumors. Cancer Sci 2015; 
106: 747-56. doi: 10.1111/cas.12672
125. Rautio J, Karkkainen J, Huttunen K, Gynther M. Amino acid ester 
prodrugs conjugated to the alpha-carboxylic acid group do not 
display affinity for the L-type amino acid transporter 1 (LAT1). 
Eur J Pharm Sci 2014; 66C: 36-40. doi: 10.1016/j.ejps.2014.09.025
126. Shoji Y, Noguchi A, Shoji Y, Matsumori M, Takasago Y, Takayanagi 
M, et al. Five novel SLC7A7 variants and y+L gene-expression 
pattern in cultured lymphoblasts from Japanese patients with 
lysinuric protein intolerance. Hum Mutat 2002; 20: 375-81. doi: 
10.1002/humu.10140
127. Torrents D, Mykkanen J, Pineda M, Feliubadalo L, Estevez R, de 
Cid R, et al. Identification of SLC7A7, encoding y+LAT-1, as the 
lysinuric protein intolerance gene. Nat Genet 1999; 21: 293-6. doi: 
10.1038/6809
128. Sperandeo MP, Paladino S, Maiuri L, Maroupulos GD, Zurzolo C, 
Taglialatela M, et al. A y(+)LAT-1 mutant protein interferes with 
y(+)LAT-2 activity: implications for the molecular pathogenesis of 
lysinuric protein intolerance. Eur J Hum Genet 2005; 13: 628-34. 
doi: 10.1038/sj.ejhg.5201376
129. Chen G, Fang Q, Zhang J, Zhou D, Wang Z. Role of the Nrf2-ARE 
pathway in early brain injury after experimental subarachnoid 
hemorrhage. J Neurosci Res 2011; 89: 515-23. doi: 10.1002/
jnr.22577
130. Cohen-Kashi-Malina K, Cooper I, Teichberg VI. Mechanisms of 
glutamate efflux at the blood-brain barrier: involvement of glial 
cells. J Cereb Blood Flow Metab 2012; 32: 177-89. doi: 10.1038/
jcbfm.2011.121
131. Sickmann HM, Waagepetersen HS. Effects of diabetes on brain 
metabolism--is brain glycogen a significant player? Metab Brain 
Omidi et al
BioImpacts, 2016, 6(4), 225-248246
Dis 2015; 30: 335-43. doi: 10.1007/s11011-014-9546-z
132. Hawkins RA. The blood-brain barrier and glutamate. Am J Clin 
Nutr 2009; 90: 867S-74S. doi: 10.3945/ajcn.2009.27462BB
133. Broer S, Brookes N. Transfer of glutamine between astrocytes and 
neurons. J Neurochem 2001; 77: 705-19. 
134. Omidi Y, Gumbleton M. Biological membranes and barriers. 
Biomaterials for Delivery and Targeting of Proteins Nucleic Acids, 
Mahato, RI (Ed): CRC Press, New York; 2005. p. 232-74.
135. Boleti H, Coe IR, Baldwin SA, Young JD, Cass CE. Molecular 
identification of the equilibrative NBMPR-sensitive (es) nucleoside 
transporter and demonstration of an equilibrative NBMPR-
insensitive (ei) transport activity in human erythroleukemia 
(K562) cells. Neuropharmacology 1997; 36: 1167-79. 
136. Chishty M, Begley DJ, Abbott NJ, Reichel A. Interaction of 
nucleoside analogues with nucleoside transporters in rat 
brain endothelial cells. J Drug Target 2004; 12: 265-72. doi: 
10.1080/10611860410001731398
137. Choi JS, Berdis AJ. Nucleoside transporters: biological insights and 
therapeutic applications. Future Med Chem 2012; 4: 1461-78. doi: 
10.4155/fmc.12.79
138. Mangravite LM, Xiao G, Giacomini KM. Localization of human 
equilibrative nucleoside transporters, hENT1 and hENT2, in renal 
epithelial cells. Am J Physiol Renal Physiol 2003; 284: F902-10. doi: 
10.1152/ajprenal.00215.2002
139. Rodriguez-Mulero S, Errasti-Murugarren E, Ballarin J, Felipe A, 
Doucet A, Casado FJ, et al. Expression of concentrative nucleoside 
transporters SLC28 (CNT1, CNT2, and CNT3) along the rat 
nephron: effect of diabetes. Kidney Int 2005; 68: 665-72. doi: 
10.1111/j.1523-1755.2005.00444.x
140. Ritzel MW, Ng AM, Yao SY, Graham K, Loewen SK, Smith KM, et 
al. Molecular identification and characterization of novel human 
and mouse concentrative Na+-nucleoside cotransporter proteins 
(hCNT3 and mCNT3) broadly selective for purine and pyrimidine 
nucleosides (system cib). J Biol Chem 2001; 276: 2914-27. doi: 
10.1074/jbc.M007746200
141. Damaraju S, Zhang J, Visser F, Tackaberry T, Dufour J, Smith KM, 
et al. Identification and functional characterization of variants in 
human concentrative nucleoside transporter 3, hCNT3 (SLC28A3), 
arising from single nucleotide polymorphisms in coding regions of 
the hCNT3 gene. Pharmacogenet Genomics 2005; 15: 173-82. 
142. Lepist EI, Damaraju VL, Zhang J, Gati WP, Yao SY, Smith KM, et al. 
Transport of A1 adenosine receptor agonist tecadenoson by human 
and mouse nucleoside transporters: evidence for blood-brain 
barrier transport by murine equilibrative nucleoside transporter 
1 mENT1. Drug Metab Dispos 2013; 41: 916-22. doi: 10.1124/
dmd.112.049858
143. Siccardi D, Gumbleton M, Omidi Y, McGuigan C. Stereospecific 
chemical and enzymatic stability of phosphoramidate triester 
prodrugs of d4T in vitro. Eur J Pharm Sci 2004; 22: 25-31. doi: 
10.1016/j.ejps.2004.02.006
144. Balzarini J, Cahard D, Wedgwood O, Salgado A, Velazquez S, 
Yarnold CJ, et al. Marked inhibitory activity of masked aryloxy 
aminoacyl phosphoramidate derivatives of dideoxynucleoside 
analogues against visna virus infection. J Acquir Immune Defic 
Syndr Hum Retrovirol 1998; 17: 296-302. 
145. Schinkel AH. P-Glycoprotein, a gatekeeper in the blood-brain 
barrier. Adv Drug Deliv Rev 1999; 36: 179-94. 
146. Borst P, Schinkel AH. P-glycoprotein ABCB1: a major player in 
drug handling by mammals. J Clin Invest 2013; 123: 4131-3. doi: 
10.1172/JCI70430
147. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. Absence 
of the mdr1a P-Glycoprotein in mice affects tissue distribution and 
pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J 
Clin Invest 1995; 96: 1698-705. doi: 10.1172/JCI118214
148. Eilers M, Roy U, Mondal D. MRP (ABCC) transporters-mediated 
efflux of anti-HIV drugs, saquinavir and zidovudine, from human 
endothelial cells. Exp Biol Med (Maywood) 2008; 233: 1149-60. doi: 
10.3181/0802-RM-59
149. Tang SC, Lagas JS, Lankheet NA, Poller B, Hillebrand MJ, Rosing H, 
et al. Brain accumulation of sunitinib is restricted by P-glycoprotein 
(ABCB1) and breast cancer resistance protein (ABCG2) and can 
be enhanced by oral elacridar and sunitinib coadministration. Int J 
Cancer 2012; 130: 223-33. doi: 10.1002/ijc.26000
150. Ogushi N, Sasaki K, Shimoda M. Effect of cyclosporin on 
distribution of methotrexate into the brain of rats. J Vet Med Sci 
2015. doi: 10.1292/jvms.14-0671
151. Zhang C, Chanteux H, Zuo Z, Kwan P, Baum L. Potential role for 
human P-glycoprotein in the transport of lacosamide. Epilepsia 
2013; 54: 1154-60. doi: 10.1111/epi.12158
152. Padan E, Landau M. Sodium-Proton (Na(+)/H(+)) Antiporters: 
Properties and Roles in Health and Disease. Met Ions Life Sci 2016; 
16: 391-458. doi: 10.1007/978-3-319-21756-7_12
153. Ganapathy V, Leibach FH. Proton-coupled solute transport in the 
animal cell plasma membrane. Curr Opin Cell Biol 1991; 3: 695-
701. 
154. Lam TI, Wise PM, O’Donnell ME. Cerebral microvascular 
endothelial cell Na/H exchange: evidence for the presence of 
NHE1 and NHE2 isoforms and regulation by arginine vasopressin. 
Am J Physiol Cell Physiol 2009; 297: C278-89. doi: 10.1152/
ajpcell.00093.2009
155. Mokgokong R, Wang S, Taylor CJ, Barrand MA, Hladky SB. Ion 
transporters in brain endothelial cells that contribute to formation 
of brain interstitial fluid. Pflugers Arch 2014; 466: 887-901. doi: 
10.1007/s00424-013-1342-9
156. Nassl AM, Rubio-Aliaga I, Fenselau H, Marth MK, Kottra G, 
Daniel H. Amino acid absorption and homeostasis in mice lacking 
the intestinal peptide transporter PEPT1. Am J Physiol Gastrointest 
Liver Physiol 2011; 301: G128-37. doi: 10.1152/ajpgi.00017.2011
157. Bockman DE, Ganapathy V, Oblak TG, Leibach FH. Localization 
of peptide transporter in nuclei and lysosomes of the pancreas. Int 
J Pancreatol 1997; 22: 221-5. doi: 10.1007/BF02788388
158. Zhou X, Thamotharan M, Gangopadhyay A, Serdikoff C, Adibi SA. 
Characterization of an oligopeptide transporter in renal lysosomes. 
Biochim Biophys Acta 2000; 1466: 372-8. 
159. Momburg F, Neefjes JJ, Hammerling GJ. Peptide selection by MHC-
encoded TAP transporters. Curr Opin Immunol 1994; 6: 32-7. 
160. Roelse J, Gromme M, Momburg F, Hammerling G, Neefjes J. 
Trimming of TAP-translocated peptides in the endoplasmic 
reticulum and in the cytosol during recycling. J Exp Med 1994; 
180: 1591-7. 
161. Tsuji A. Tissue selective drug delivery utilizing carrier-mediated 
transport systems. J Control Release 1999; 62: 239-44. 
162. Zhang Y, Sun J, Sun Y, Wang Y, He Z. Prodrug design targeting 
intestinal PepT1 for improved oral absorption: design and 
performance. Curr Drug Metab 2013; 14: 675-87. 
163. Sugawara M, Huang W, Fei YJ, Leibach FH, Ganapathy V, 
Ganapathy ME. Transport of valganciclovir, a ganciclovir prodrug, 
via peptide transporters PEPT1 and PEPT2. J Pharm Sci 2000; 
89: 781-9. doi: 10.1002/(SICI)1520-6017(200006)89:6<781::AID-
JPS10>3.0.CO;2-7
164. Smith MW, Gumbleton M. Endocytosis at the blood-brain barrier: 
from basic understanding to drug delivery strategies. J Drug Target 
2006; 14: 191-214. doi: 10.1080/10611860600650086
165. Rajendran L, Knolker HJ, Simons K. Subcellular targeting strategies 
for drug design and delivery. Nat Rev Drug Discov 2010; 9: 29-42. 
doi: 10.1038/nrd2897
166. Omidi Y, Hollins AJ, Benboubetra M, Drayton R, Benter IF, 
Akhtar S. Toxicogenomics of non-viral vectors for gene therapy: 
a microarray study of lipofectin- and oligofectamine-induced gene 
expression changes in human epithelial cells. J Drug Target 2003; 
11: 311-23. doi: 10.1080/10611860310001636908
167. Omidi Y, Barar J, Akhtar S. Toxicogenomics of cationic lipid-based 
vectors for gene therapy: impact of microarray technology. Curr 
Drug Deliv 2005; 2: 429-41. 
168. Omidi Y, Barar J, Heidari HR, Ahmadian S, Yazdi HA, Akhtar 
S. Microarray analysis of the toxicogenomics and the genotoxic 
potential of a cationic lipid-based gene delivery nanosystem in 
human alveolar epithelial a549 cells. Toxicol Mech Methods 2008; 
BBB transporters and targeted therapy of brain diseases
BioImpacts, 2016, 6(4), 225-248 247
18: 369-78. doi: 10.1080/15376510801891286
169. Nomani A, Haririan I, Rahimnia R, Fouladdel S, Gazori T, 
Dinarvand R, et al. Physicochemical and biological properties 
of self-assembled antisense/poly(amidoamine) dendrimer 
nanoparticles: the effect of dendrimer generation and charge ratio. 
Int J Nanomedicine 2010; 5: 359-69. 
170. Kafil V, Omidi Y. Cytotoxic impacts of linear and branched 
polyethylenimine nanostructures in a431 cells. Bioimpacts 2011; 1: 
23-30. doi: 10.5681/bi.2011.004
171. Barar J, Aghanejad A, Fathi M, Omidi Y. Advanced drug delivery 
and targeting technologies for the ocular diseases. Bioimpacts 
2016; 6: 49-67. doi: 10.15171/bi.2016.07
172. Schlachetzki F, Zhu C, Pardridge WM. Expression of the neonatal 
Fc receptor (FcRn) at the blood-brain barrier. J Neurochem 2002; 
81: 203-6. 
173. Schnitzer JE. gp60 is an albumin-binding glycoprotein expressed 
by continuous endothelium involved in albumin transcytosis. Am J 
Physiol 1992; 262: H246-54. 
174. Vogel SM, Minshall RD, Pilipovic M, Tiruppathi C, Malik AB. 
Albumin uptake and transcytosis in endothelial cells in vivo 
induced by albumin-binding protein. Am J Physiol Lung Cell Mol 
Physiol 2001; 281: L1512-22. 
175. Caram-Salas N, Boileau E, Farrington GK, Garber E, Brunette E, 
Abulrob A, et al. In vitro and in vivo methods for assessing FcRn-
mediated reverse transcytosis across the blood-brain barrier. 
Methods Mol Biol 2011; 763: 383-401. doi: 10.1007/978-1-61779-
191-8_26
176. Cooper PR, Ciambrone GJ, Kliwinski CM, Maze E, Johnson 
L, Li Q, et al. Efflux of monoclonal from rat brain by neonatal 
Fc receptor, FcRn. Brain Res 2013; 1534: 13-21. doi: 10.1016/j.
brainres.2013.08.035
177. Christianson GJ, Sun VZ, Akilesh S, Pesavento E, Proetzel G, 
Roopenian DC. Monoclonal antibodies directed against human 
FcRn and their applications. MAbs 2012; 4: 208-16. doi: 10.4161/
mabs.4.2.19397
178. Piper RC, Luzio JP. Late endosomes: sorting and partitioning in 
multivesicular bodies. Traffic 2001; 2: 612-21. 
179. Dice JF. Selective degradation of cytosolic proteins by lysosomes. 
Ann N Y Acad Sci 1992; 674: 58-64. 
180. Luzio JP, Pryor PR, Gray SR, Gratian MJ, Piper RC, Bright NA. 
Membrane traffic to and from lysosomes. Biochem Soc Symp 2005; 
77-86. 
181. Dice JF, Terlecky SR. Targeting of cytosolic proteins to lysosomes 
for degradation. Crit Rev Ther Drug Carrier Syst 1990; 7: 211-33. 
182. Razani B, Woodman SE, Lisanti MP. Caveolae: from cell biology to 
animal physiology. Pharmacol Rev 2002; 54: 431-67. 
183. Gumbleton M. Caveolae-mediated membrane transport. Adv Drug 
Deliv Rev 2001; 49: 217-21. 
184. Gumbleton M, Hollins AJ, Omidi Y, Campbell L, Taylor G. 
Targeting caveolae for vesicular drug transport. J Control Release 
2003; 87: 139-51. 
185. DeGrella RF, Simoni RD. Intracellular transport of cholesterol to 
the plasma membrane. J Biol Chem 1982; 257: 14256-62. 
186. Kaplan MR, Simoni RD. Transport of cholesterol from the 
endoplasmic reticulum to the plasma membrane. J Cell Biol 1985; 
101: 446-53. 
187. Xu L, Guo R, Xie Y, Ma M, Ye R, Liu X. Caveolae: molecular insights 
and therapeutic targets for stroke. Expert Opin Ther Targets 2015; 
19: 633-50. doi: 10.1517/14728222.2015.1009446
188. Bertino EM, Williams TM, Nana-Sinkam SP, Shilo K, Chatterjee 
M, Mo X, et al. Stromal Caveolin-1 Is Associated With Response 
and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin 
for Advanced NSCLC Patients. Clin Lung Cancer 2015; 16: 466-74. 
doi: 10.1016/j.cllc.2015.05.004
189. Sripriyalakshmi S, Anjali CH, George PD, Rajith B, Ravindran 
A. BSA nanoparticle loaded atorvastatin calcium--a new facet 
for an old drug. PLoS One 2014; 9: e86317. doi: 10.1371/journal.
pone.0086317
190. Hwang ME, Keswani RK, Pack DW. Dependence of PEI and 
PAMAM Gene Delivery on Clathrin- and Caveolin-Dependent 
Trafficking Pathways. Pharm Res 2015; 32: 2051-9. doi: 10.1007/
s11095-014-1598-6
191. Bohmer N, Jordan A. Caveolin-1 and CDC42 mediated endocytosis 
of silica-coated iron oxide nanoparticles in HeLa cells. Beilstein J 
Nanotechnol 2015; 6: 167-76. doi: 10.3762/bjnano.6.16
192. Popova NV, Deyev IE, Petrenko AG. Clathrin-mediated 
endocytosis and adaptor proteins. Acta Naturae 2013; 5: 62-73. 
193. Godlee C, Kaksonen M. Review series: From uncertain beginnings: 
initiation mechanisms of clathrin-mediated endocytosis. J Cell Biol 
2013; 203: 717-25. doi: 10.1083/jcb.201307100
194. Miller SE, Mathiasen S, Bright NA, Pierre F, Kelly BT, Kladt N, et 
al. CALM regulates clathrin-coated vesicle size and maturation by 
directly sensing and driving membrane curvature. Dev Cell 2015; 
33: 163-75. doi: 10.1016/j.devcel.2015.03.002
195. Zhu J, Zhou K, Hao JJ, Liu J, Smith N, Zhan X. Regulation of 
cortactin/dynamin interaction by actin polymerization during 
the fission of clathrin-coated pits. J Cell Sci 2005; 118: 807-17. doi: 
10.1242/jcs.01668
196. Smythe E. Role of the rab5 guanine nucleotide exchange factor, 
Rme-6, in the regulation of clathrin-coated vesicle uncoating. 
Methods Mol Biol 2015; 1298: 283-93. doi: 10.1007/978-1-4939-
2569-8_24
197. Monsalve Y, Tosi G, Ruozi B, Belletti D, Vilella A, Zoli M, et al. 
PEG-g-chitosan nanoparticles functionalized with the monoclonal 
antibody OX26 for brain drug targeting. Nanomedicine (Lond) 
2015; 10: 1735-50. doi: 10.2217/nnm.15.29
198. Liu Z, Zhao H, Shu L, Zhang Y, Okeke C, Zhang L, et al. 
Preparation and evaluation of Baicalin-loaded cationic solid 
lipid nanoparticles conjugated with OX26 for improved delivery 
across the BBB. Drug Dev Ind Pharm 2015; 41: 353-61. doi: 
10.3109/03639045.2013.861478
199. Liu Z, Zhang L, He Q, Liu X, Okeke CI, Tong L, et al. Effect of 
Baicalin-loaded PEGylated cationic solid lipid nanoparticles 
modified by OX26 antibody on regulating the levels of baicalin 
and amino acids during cerebral ischemia-reperfusion in rats. Int J 
Pharm 2015; 489: 131-8. doi: 10.1016/j.ijpharm.2015.04.049
200. Yue PJ, He L, Qiu SW, Li Y, Liao YJ, Li XP, et al. OX26/CTX-
conjugated PEGylated liposome as a dual-targeting gene 
delivery system for brain glioma. Mol Cancer 2014; 13: 191. doi: 
10.1186/1476-4598-13-191
201. Bao H, Jin X, Li L, Lv F, Liu T. OX26 modified hyperbranched 
polyglycerol-conjugated poly(lactic-co-glycolic acid) 
nanoparticles: synthesis, characterization and evaluation of its 
brain delivery ability. J Mater Sci Mater Med 2012; 23: 1891-901. 
doi: 10.1007/s10856-012-4658-7
202. Pang Z, Lu W, Gao H, Hu K, Chen J, Zhang C, et al. Preparation 
and brain delivery property of biodegradable polymersomes 
conjugated with OX26. J Control Release 2008; 128: 120-7. doi: 
10.1016/j.jconrel.2008.03.007
203. Aktas Y, Yemisci M, Andrieux K, Gursoy RN, Alonso MJ, 
Fernandez-Megia E, et al. Development and brain delivery of 
chitosan-PEG nanoparticles functionalized with the monoclonal 
antibody OX26. Bioconjug Chem 2005; 16: 1503-11. doi: 10.1021/
bc050217o
204. Gosk S, Vermehren C, Storm G, Moos T. Targeting anti-transferrin 
receptor antibody (OX26) and OX26-conjugated liposomes 
to brain capillary endothelial cells using in situ perfusion. J 
Cereb Blood Flow Metab 2004; 24: 1193-204. doi: 10.1097/01.
WCB.0000135592.28823.47
205. Wang L, Hao Y, Li H, Zhao Y, Meng D, Li D, et al. Co-delivery 
of doxorubicin and siRNA for glioma therapy by a brain 
targeting system: angiopep-2-modified poly(lactic-co-glycolic 
acid) nanoparticles. J Drug Target 2015; 23: 832-46. doi: 
10.3109/1061186X.2015.1025077
206. Cabezon I, Manich G, Martin-Venegas R, Camins A, Pelegri C, 
Vilaplana J. Trafficking of Gold Nanoparticles Coated with the 
8D3 Anti-Transferrin Receptor Antibody at the Mouse Blood-
Brain Barrier. Mol Pharm 2015; 12: 4137-45. doi: 10.1021/acs.
Omidi et al
BioImpacts, 2016, 6(4), 225-248248
molpharmaceut.5b00597
207. Zhang B, Sun X, Mei H, Wang Y, Liao Z, Chen J, et al. LDLR-
mediated peptide-22-conjugated nanoparticles for dual-targeting 
therapy of brain glioma. Biomaterials 2013; 34: 9171-82. doi: 
10.1016/j.biomaterials.2013.08.039
208. Cui Y, Xu Q, Chow PK, Wang D, Wang CH. Transferrin-conjugated 
magnetic silica PLGA nanoparticles loaded with doxorubicin and 
paclitaxel for brain glioma treatment. Biomaterials 2013; 34: 8511-
20. doi: 10.1016/j.biomaterials.2013.07.075
209. Tosi G, Badiali L, Ruozi B, Vergoni AV, Bondioli L, Ferrari A, et al. 
Can leptin-derived sequence-modified nanoparticles be suitable 
tools for brain delivery? Nanomedicine (Lond) 2012; 7: 365-82. doi: 
10.2217/nnm.11.98
210. Tzeng SY, Green JJ. Therapeutic nanomedicine for brain cancer. 
Ther Deliv 2013; 4: 687-704. doi: 10.4155/tde.13.38
211. Su Z, Xing L, Chen Y, Xu Y, Yang F, Zhang C, et al. Lactoferrin-
modified poly(ethylene glycol)-grafted BSA nanoparticles as a 
dual-targeting carrier for treating brain gliomas. Mol Pharm 2014; 
11: 1823-34. doi: 10.1021/mp500238m
212. Clark AJ, Davis ME. Increased brain uptake of targeted 
nanoparticles by adding an acid-cleavable linkage between 
transferrin and the nanoparticle core. Proc Natl Acad Sci U S A 
2015; 112: 12486-91. doi: 10.1073/pnas.1517048112
213. Han L, Kong DK, Zheng MQ, Murikinati S, Ma C, Yuan P, et al. 
Increased Nanoparticle Delivery to Brain Tumors by Autocatalytic 
Priming for Improved Treatment and Imaging. ACS Nano 2016; 
10: 4209-18. doi: 10.1021/acsnano.5b07573
214. Zong T, Mei L, Gao H, Cai W, Zhu P, Shi K, et al. Synergistic dual-
ligand doxorubicin liposomes improve targeting and therapeutic 
efficacy of brain glioma in animals. Mol Pharm 2014; 11: 2346-57. 
doi: 10.1021/mp500057n
215. Wei L, Guo XY, Yang T, Yu MZ, Chen DW, Wang JC. Brain tumor-
targeted therapy by systemic delivery of siRNA with Transferrin 
receptor-mediated core-shell nanoparticles. Int J Pharm 2016; 510: 
394-405. doi: 10.1016/j.ijpharm.2016.06.127
216. Zhang TT, Li W, Meng G, Wang P, Liao W. Strategies for transporting 
nanoparticles across the blood-brain barrier. Biomater Sci 2016; 4: 
219-29. doi: 10.1039/c5bm00383k
217. Cheng Y, Morshed RA, Auffinger B, Tobias AL, Lesniak MS. 
Multifunctional nanoparticles for brain tumor imaging and 
therapy. Adv Drug Deliv Rev 2014; 66: 42-57. doi: 10.1016/j.
addr.2013.09.006
